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The therapeutic/pharmacological effects of Copper (II) or its complexes with organic ligands 
have in the past three decades received much attention, and this is partly, because copper (II) 
complexes have been reported to be good in alleviating inflammation associated with rheumatoid 
arthritis.   Therefore this study describes the investigation of the solution chemistry of the copper 
(II) complexes of homopiperazine and an adamentane derivative of homopiperazine (PCU.homo) 
using glass electrode potentiometry, UV/VIS spectroscopy, speciation modeling, nuclear 
magnetic resonance spectroscopy, blood plasma modeling, and dermal absorption. 
 







) using a glass electrode. For PCU.homo-Cu(II), the MLH species predominated 
(reaching ≈ 80 %) under physiological conditions.   The determination of the formation constants 
of PCU.homopiperazine-Zn(II) complex was complicated by the formation of a precipitate at 
high pH values (i.e. pH values ≥ 7).  
 
The structures of the complexes formed in solution were determined using N M R. spectroscopy 
and UV/VIS spectroscopy.   These results indicated that in the ML species only 3 amine donor 
groups are coordinated to the metal ion (i.e. MN3-[H2O]3 type of coordination), while for the 
MLH species only one side of the ligand was coordinated to Cu(II).   MM calculation supported 
the experimental structures. 
  
The plasma mobilizing index of Cu(II)-(PCU.homo) complex was calculated using ECCLES 
(Evaluation of Constituent Concentration in Large Equilibrium System).   The model showed that 
PCU.homopiperazine is not good in mobilizing copper in vivo, even at high ligand concentration.  
 
Tissue permeability studies were performed using a modified Franz cell and a cerasome 9005 
membrane, where, Kp (permeability coefficient) was found to be 5.06 x 10
-6 
cm/s (± 0.03).   These 



















LIGAND ABBREVIATIONS USED 
 
PCUA                             -3.5-bis [ethanediamine]-4-[oxahexacyclododecane] 
EN                                  -Ethylenediamine 
Gly                              -Glycinate 
DTPA                           -diethylenetriamine-N,N,N’,N’’,N”-pentaacetic aicd 
             EDTA                             - Ethylenediaminetertraacetic acid 
              HP                              - homopiperazine or 1,4diazacycloheptane 
 H(555-N)                    -N-(2-(2-aminoethyl)ethyl)picolinamide 
              PCU.homo          -N, N’-bis [1, 4diazacycloheptane]-4-[oxahexacyclododecane] 
PCU.EN                          -N, N’-bis [ethylene diamine]-4-[oxahexacyclododecane] 
             Ttda                            -3, 6, 9, 12-tetraazatetradecanedioic acid 
Dtda                            -N, N’-(bis [2-(dimethylamino) ethyl]-ethanediamine) H2 
PrDH                             -N,N’-di(aminoethylene)-2,6-pyridine-dicarbonylamine 
























OTHER ABBREVIATIONS USED 
 
R.A                           –Rheumatoid arthritis 
NSAIDs                   -Nonsteroidal anti-inflammatory drugs 
COX (II)                  -Cyclo-oxygenase enzyme 
DMARDs                 -Disease- modifying anti-rheumatic drugs 
SOD                         -Superoxide dismutase 
HSA                         -Human serum albumin 
CP                            -Ceruloplasmin 
UV                            -Ultraviolet  
VIS                           -Visible spectroscopy 
ESTA                     -Equilibrium Simulation for Titration Analysis 
TH                          -total proton concentration (mol/dm
3
) 
TL                           -total ligand concentration (mol/dm
3
) 
TM                         -total metal concentration (mol/dm
3
) 
KW                         -dissociation constant of water 
Ecell                          -electrode potential (volts) 
Eº                             -electrode response intercept (volts) 





T                               -absolute temperature (Kelvin) 
F                               -Faraday constant 
[H
+
]                          -hydrogen ion activity 
s                               - Electrode slope 
RH                              -Hamiltonian R-factor 
Rlim
H
                          -Hamiltonian R-limit 














             ZH-bar                       -Protonation function 
ZM-bar                        -Complex formation function 
Q-bar                          -Deprotonation function 
SPEC                          -Task to calculate the speciation in solution 
logβ                            - log equilibrium constant (log beta) 
p q  r                              - symbols representing the stochiometry of the reacting species   
KHP                               -Potassium hydrogen phthalate 
2D NMR  - Two dimensional Nuclear Magnetic Resonance spectroscopy. 
ECCLES  -Evaluation of Constituent Concentration in Large Equilibrium     
Systems 
             [L]                                  -free ligand concentration 
            p.m.i                                -Plasma mobilizing index 
l.m.w                               -low molecular weight 
λmax                                 -frequency of maximum absorption 
Utotal                                 -total strain energy 
∑Eb                                 -total bond deformation energy 
∑EӨ                                -total valence angle deformation energy 
∑EΦ                                -total torsion (or dihedral) deformation energy 
∑Enb                                -total non-bonded (van der waals) interaction energy 
r                                      -ideal bond length 
 Ө                                   -bond angle 
 Ø                                   -dihedral angle 

















Structural Formulae of ligands used or discussed in this Study 
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1. RHEUMATOID ARTHRITIS 
1.1 Introduction 
Rheumatoid arthritis is a chronic, progressive disease in which inflammation changes occur 
throughout the connective tissues of the body [1], with its symptoms appearing in the same joints 
on both sides of the body.   Joints that are susceptible to RA attack include joints of fingers, wrist 
(as shown in Figure 1.1), elbows, knuckles and knees [1].   
                                       
                           
                                      Figure 1.1 picture of a hand affected with RA   
Rheumatoid arthritis has been reported to affect 5% of the population of developing countries, 
with 50% of these cases reported as acute infections [2].   It normally attacks people between the 
ages of 25 and 50 and it has been reported as being more prevalent in women than in men [1-2].   
It has also been found to occur in children where it is referred to as juvenile poly-arthritis [1, 3].    
The disease is believed to be caused by a faulty autoimmune response where hydrolytic enzymes 
which include, collagenases, proteases, gelatinases and matrilysin are released inside cells present 
at the sites of tissue injury, and this results in the degradation of collagen and other structural 














damage (see Figure 1.1) [4].   This follows from the fact that 90% of the reported cases of people 
diagnosed with rheumatoid arthritis have been found to contain high levels of a certain 
autoantibody in their blood serum [4].   This autoantibody (auto-immunoglobin) is called 
Rheumatoid factor.   The specific antigen that causes this cascade (autoimmune response) of 
reactions is still not known [1, 3, 5-6].    
Even though RA is generally referred to as a joint disease (synovitis) its symptoms may manifest 
in ways not directly associated with the joints [1-2].   This includes: blood-vessel inflammation in 
the form of necrosis in the fingertips, chronic leg ulcers and lesions in the peripheral nerves, 
inflammation and nodule formation in the lungs and pleura (tissue covering the lung) [1].                                                
1.2 Treatment of symptoms of Rheumatoid Arthritis 
There is no cure for this debilitating disease [5].   This is mainly due its poorly understood 
pathogenic mechanism [2-3].   However the disease is controlled by immunosuppressive drugs 
and its symptoms are treated with anti-inflammatory drugs [1-3].   An effective treatment 
program for arthritis involves drug therapy (steroidal or non-steroidal drugs), exercise and rest 
[5].  In most cases of RA, patients have complete remission and exacerbations of the symptoms 
[6], therefore early therapy is very important in relieving the early symptoms associated with RA 
[4].   Appearance of subcutaneous rheumatoid nodules in the shoulder joint can also help to 
diagnose the disease faster [1, 6].   Surgery is often of value in correcting established joint 
deformities [4, 6-7].   Therapeutic/ anti-inflammatory drugs that are normally given to treat R.A. 
patients fall into three categories; discussed in the next sections. 
1.2.1 Nonsteroidal anti-inflammatory drugs (NSAIDs) 
Nonsteroidal anti-inflammatory drugs (NSAIDs) are reported to form the first line of anti-














They are thought to reduce inflammation and pain by inhibiting the activity of cyclo-oxygenase 
enzyme [7].   Cyclo-oxygenase has been linked to the catalytic production of pro-inflammatory 
immunoglobulins called prostaglandin (PG’s) and leukotriennes in the synovial cells by oxidizing 
arachidonic acid [7].   Examples of NSAIDs include Ibrufen, Naproxen and Diclofenac sodium 
(Voltaren).   Ibrufen and Voltaren have been recommended by clinics for pain relief, and to 
reduce inflammation in RA if taken in full doses [5].   The recommended dosage is 1200 to 3200 
milligrams per day in 3 or 4 doses and 100 to 200 milligrams per day in 2 and 3 doses 
respectively [5].   However the continued use of these types of drugs results in severe side effects, 
such as gastrointestinal ulcers, and kidney damage.   NSAIDs have also been reported to interfere 
with the repair of superficial injury and suppression of gastric prostaglandin synthesis [5-8].   To 
try and improve the effects that NSAIDs have on the stomach lining, new drugs have been 
developed as alternative for NSAIDs [7-8].   They are called cyclooxygenase-2 (COX-2) 
inhibitors which are milder on the stomach lining [7-8].   However the setback of these drugs is 
their inability to change the outcome of the disease [8]. 
1.2.2 Glucoticosteroids  
The use of adrenal corticosteroid (sometime referred to as simply steroids) has been reported to 
produce dramatic improvement on the disease, but its effectiveness is reported to diminish with 
time [4-6].   The use of this hormone like molecule is reported to have both metabolic and 
physiological effects such as increased susceptibility to further infections, appearance of peptic 
ulcers, affecting lymphocytes, granulocytes and as well as inhibiting the immune system [4, 6, 9].   
It first received popularity as a symptomatic drug in the 1950s after Hench et al. reported its 
dramatic effect in reducing the symptoms of RA [8, 10]. 
Cortisone has been reported to bring relief to the symptoms of RA, but has received criticism 














use as part of a proper anti-rheumatic therapy has been reported as valuable during the treatment 
of arthritis.   The required dosage is 5 mg to 7.5 mg per daily dose of cortisone, which is 
administered via injection.   It is normally given to women after child birth [5, 7].  
1.2.3 Disease modifying anti-rheumatoid drugs (DMARD) 
There is a second line of anti-rheumatic drugs that has been reported to produce durable 
remissions and delay or halt diseases progression by diverting the course of the pathologic 
reaction associated with rheumatoid arthritis (RA) [6-8].   These include use of low dosages of 
azathioprine, cyclosporin (cyclosporine A), D-penicillamine, gold salts, hydroxychloroquine, 
Leflunomide, Methotrexate, Minocycline, and biological agents [6, 8].    
These drugs can be divided further into two classes namely: disease modifying antirheumatic 
drugs (DMARDs) and biologic agents [7-8].   DMARDs re often required to reverse the disease 
process and prevent long-term damage [8].   In particular they prevent bone and joint damage 
from occurring secondary to the uncontrolled inflammation [8].   Classic examples of DMARDs 
include methotrexate and sulfasalzine [7-10].   Early therapy with methotrexane has been reported 
as being effective in stopping the early process of RA, which involves the joints being infiltrated 
by cells of the immune system that signal to one another and are thought to set up a self-
pertuating chronic inflammation [3-4].   Biological agents are a new type of drug that decrease or 
stop the progress of RA [10].   They act as response modifiers that block specific immune factors 
that lead to RA [10].  This is following the recognition of prostaglandins (PG’s) as an important 
component of the body’s inflammation reaction.   People who do not respond well to the first 
with DMARDs treatment are given an option to use protein-A immuno adsorption (Prosorba) 
therapy.  Other examples of these biological agents include tumour necrosis factor alpha (TNFα) 
blockers, Infliximab (Remicade), and adalimab (Humira) [5, 10].   The problem with these new 














1.3 Background to study 
1.3.1 Metals in living systems 
Trace metal ions are important in the normal functioning of both plants and animals [12].   
Examples include cobalt, copper, iron, nickel, molybdenum, selenium and zinc [9].   Some of 
their roles include taking part in metabolism and growth processes or forming part of the skeletal 
system of biological molecules, such as Co(I) in vitamin B12, and Fe(II) in haemoglobin.   They 
can also be used to disrupt skeletal structure of biological molecules such when they are used in 
anti-bacterial agents [9].   However metal ion requirement by plant and animals species varies 
greatly from species to species [9, 12].   Much of the energy expended by an organism is used to 
maintain the correct concentration and speciation of metal ions in different cells.  This is called 
homeostasis [9, 12-13].   A change in metal ion speciation may result in poor health or even 
retarded growth in some organisms [12].   Imbalances in metal homeostasis can also be caused by 
external factors such as smoking and the over use of prescription medication [11-12].   As a result 
a number of disorders occurring in humans have been linked or associated to levels of trace 
metals found in the body, with the disease controlled by either replenishing the specific metal ion 
concentration in the body from an exogenous source or by removing the excess metal ion from 
the body using a specific metal chelating agent [13].   Examples include lung and breast cancer 
which have been associated with low levels of selenium, Wilson disease which results in an 
accumulation of copper in the tissues of the liver, brain and kidneys [4, 9].   The symptoms of 
Wilson’s disease can be treated with a daily dose of 50 milligrams of zinc taken with each meal; 
zinc is reported to effectively lower the abnormal accumulation of copper in people afflicted with 
this genetic disease of copper metabolism. Other examples include kidney stone formation which 














There are metals that are not essential and are toxic, but still manage to find their way into the 
body of living systems [16-17].   This is mainly caused by human’s bad environmental 
management practices.   Examples of these nonessential elements include lead, cadmium, and 
mercury.  Out of all the trace elements described in the literature, copper is the metal which is 
mostly associated with the development of many metal dependent disorders occurring in the 
human body, examples include RA and enkephalins [14-17].  
1.3.2 Bio-distribution of copper (II) and the involvement of copper (II) in RA. 
Copper was first recognised as an essential element in 1921, after copper salts were shown to be 
active against anemia which was caused by a copper defiencient diet in animal models [9-10].  
Since then scientists in this field of chemo-therapy agree on two facts when designing or 
developing novel therapeutic/chemotherapeutic agents.   These include: knowledge of what 
happens at the molecular level during the onset of the disease is of value (i.e.  Knowledge of how 
the body functions at the molecular is very important) [9-10] and that for a metal ion to be able to 
perform its biological role it must be bioavalable (i.e. it must be in a state/form were the body can 
access it).   Essential metals such as zinc, copper, and iron achieve these by binding to some sort 
of a biological molecule normally apoproteins or apoenzymes.   Copper in nature exists in three 
oxidation states, Cu(I), Cu(II) and Cu(III) [9, 10].   Like other essential amino acids, fatty acids, 
or vitamins, copper is not synthesized in the body and sources of this essential nutrient include 
dried beans, nuts, animal liver, and crustacean [4, 9]  
The body contains between 50 and 120 milligrams of copper [10, 11].   Copper from an 
exogenous source, enters the body via rapid absorption through the stomach and small intestine 
(jejunum) by a facilitated diffusion, using transport proteins to help copper to pass-through the 
phospholipid membranes and it is finally stored in the liver via ligand exchange processes in the 














to be bound either to transport proteins (ceruloplasmin and serum albumin), storage proteins 
(metallothioniens) or copper containing enzymes and low molecular weight complexes of copper 
[9].   It also forms part of our most important antioxidant enzymes, copper- zinc superoxide 
dismutase [9].   Other important functions of copper in the body include bone formation, 
keratinisation, reproduction, fertility, development of central and peripheral nervous systems, 
cardiac function, cellular respiration, nerve function, extracellular connective tissue formation, 
pigmentation and regulation of monoamine concentration [4, 8-9].   The amount of copper in each 
tissue correlates with the number and kind of metabolic processes requiring copper in that 
particular tissue [3, 6-7].   Excess copper is moved out of the body though biliary excretion [3, 7-
8].   Furthermore these biological roles of copper are dependent on copper existing as a complex 
at the active site following complexation to a specific enzyme or protein [5-7].   Even though the 
stored copper-complexes are normally released by the liver into the blood to fulfil metabolic 
needs, they are also reported to be released as part of an acute-phase response during many 
disease states [6, 8, 9, 10, 14].  
The medicinal property of copper and the anti-inflammatory agent salicin has been known for 
more than a century [5].   However interest in the beneficial effects of copper (II) complexes was 
renewed by Sorenson’s report in 1976, which stated that the active forms of anti-inflammatory 
drugs are their Cu-complexes of such drugs in vivo. These analogues were also reported to be 
more active than their parent drug or inorganic copper salts [16].  The use of copper bangle to 
suppress inflammation associated with RA has been known for a very long-time [4, 9, 10].   
Walker et al. have measured the dermal absorption from these bracelets and found it to be 
significant [6]. . 
In metal-tissue distribution studies of copper in individuals with rheumatoid arthritis, elevated 
levels of serum copper were found during the inflammatory stage of the disease [14-16].   A two 














was found in the blood of these individuals and this has been linked to the severity of the disease 
state [11, 17].   Furthermore the accumulation of copper-thionine in the liver decreases [11, 17, 
18].   Since serum copper-containing components are synthesized in the liver and appear in serum 
after the onset of the disease, it seems reasonable to suggest that this is a physiologic response to 
arthritis, which facilitates remission [11, 12]. 
 The l.m.w copper complexes are believed to be involved in the transportation of copper between 
cells in the body; this is because they are formally uncharged [11].   Furthermore, it is the 
decrease of these copper complexes in the body that is thought to increase the progression of RA.   
L.m.w copper complexes are also reported to have superoxide dismutase activity by controlling 
the hydroxide and superoxide radical levels in the blood serum [12]. Hydroxide and superoxide 
radicals have been associated with development inflammation in tissues [6, 9, 11, 12].   Some of 
the other functions performed by low molecular weight complexes include acting as intermediates 
in the process of metal ions release from the storage metalloenzymes, controlling redox potential 
and keeping metal ion in solution [11].  
Ceruloplasmin has been reported to bind copper irreverserblily and therefore can be used in the 
transport of copper, but this will require denaturing of the protein at the injury site/target cell in 
order to release the metal [13].   This copper transport process has been reported to be dependent 
on copper redox activity (i.e. Cu(II) to Cu(I))[12, 13].   However the denaturing of the protein has 
severe side effects as ceruloplasmin has been shown to be involved in preventing cellular 
destruction; this is thought to account for the sudden increase of this protein in the blood during 
RA [12, 14].   Because of the increased interest in the role of l.m.w-copper complexes as potential 
anti-inflammatory agents a series of review papers have been published [14, 15], describing the 
synthesis of low molecular weight compounds that posses the potential of behaving as anti-
inflammatory drugs.   Examples of this compounds include indoles, hydroxyquinoline (Cu(II)-8-














allylthiouredobenzoate], and copper salicylates [2].   It was suggested that copper complexes of 
clinically used anti-arthritic drugs are responsible for the beneficial anti-arthritic effects of these 
drugs [16].   This is supported by the early observation by Sorenson’s that copper complexes of 
many non-anti-inflammatory complexing agents have anti-inflammatory activity in animal 
models.   This includes amino acids, amines and heterocyclic carboxylic acids.   In addition some 
copper complexes of anti-arthritic drugs were also reported to show superoxide dismutase (SOD)-
like activity in vivo, with decreased progression of RA and relatively low gastrointestinal toxicity 
in animal models compared to the normally used parent drugs [5, 11-19].   Examples of these 
anti-arthritic drugs include penicillamine and 1-phenyl-5-aminotetrazol [16].   It is worth 
mentioning that the anti-inflammatory activities reported for the compounds mentioned above 
were obtained via direct injection of the copper complexes into the blood of the studied rats [16]. 
Even though these drugs have been known for a long period of time, little is known about how 
they regulate inflammation and copper metabolism.   Care has to be taken when using copper (II) 
complexes as they have been implicated as catalysts in the formation of deleterious OH
·
 radicals 
in the Fenton reaction in the foot oedema model [12].  
There are several possible biochemical mechanisms that can account for the anti-inflammatory 
activity of copper (II) complexes. These include:  
Inducing lysyl oxidase activity (enzyme involved in the tissue repair process), this follows the 
observation that low levels of lysyl oxidase enzyme are present in a copper deficient chicken and 
its activity was increased by injecting the chicken with exogenous copper (II) sulphate salt.  
 The modulation of protastagladin synthesis by decreasing the production of a pro-inflammatory 














above).   Decreasing the permeability of human synovial lysosome and modulating the 
physiological effect of histamine [2]. 
In order to improve the bioavailability of copper and hence improve the efficacy of these 






was found to form more stable complexes with Cu(II) [18].   This high stability of the complex 
was attributed to the ease with which copper deprotonates the donor nitrogen atom of the amide 
groups.   Although the Cu(II)-L
a
 complex was neutral under physiological conditions, it was 
reported to be hydrophilic and plasma model (in vivo) calculations revealed that the complex will 
dissociate in blood plasma [18].   This meant that further work was needed to improve the 
lipophilicity of this ligand and the stability of the resulting copp r-complexes.  Therefore ligands 
Ttda and Dtda were synthesised and their solution chemistry investigated against copper (II).   It 
was reported that Ttda (β110 = 21.36) formed more stable complexes with copper (II) than Dtda 
(β110 = 19.16), but it was found that Ttda was t o hydrophilic.  Therefore resulting in the complex 
being readily excreted in urine while still intact [19]. 
  
However all was not lost as this drug could 
be used in the treatment of Wilson’s disease due to the high affinity of this ligand for copper (II) 
in vivo.   Dtda on the other-hand was reported to form weaker complexes than expected.   This 
was accounted for by the ring strain that occurs in the macro-cycle, which is caused by the 
distorted geometry around the copper (II) ion [19].   As a result the complex was reported to 
dissociate in vivo and was excreted slowly via the liver.   It was also suggested that the presence 
of an amide group provided a site for the addition of more hydrophobic groups that could help 
increase the ligand’s liphophilicity [19].   In view of the circumstantial evidence surrounding the 
use of copper in the treatment of the inflammation accompanying RA, we have embarked on a 














selectively and be able to transfer the metal ion complex across cell membranes to the sites where 
it will exert its pharmacological activity.  
 
1.4 Ligand properties and design 
According to our hypothesis, for an agent to be accepted as an anti-inflammation drug, it must be 
able to increase the supply of copper to the sites of injury (i.e. increase concentration of free 
labile copper in the synovial fluid). It must, therefore, fulfil certain design requirements discussed 
below: 
 Looking at the complexity of the human body, firstly the copper chelating agents must be able to 
bind copper (II) selectively, without disrupting the homeostasis of the other trace metals found in 
the body and it must also form lipophilic complexes with copper so that it can cross bio-
membranes.  
The ligand must be able to form labile complexes with copper so that the copper can be released 
when required. 
The ligand must also be a strong chelator of copper, but one needs to be careful that the ligand is 
not too strong a binder of copper, because it might end up being excreted with copper still bound 
to it. 
To increase its selectivity for the binding of copper (II), the ligand must have predominantly 
nitrogen donor atoms (see Figure 1.2).   This is because Cu(II) is a soft/borderline HSAB acid 
while its major in vivo competitors, Ca(II) and Zn(II) are hard acids.   Thus the use of nitrogen 
donor ligands, as opposed to oxygen donor ligands will be favour the complexation of Cu(II).   














If the agent is to be administered dermally it must be able to be absorbed through the skin.  For 
this to happen, the complex must not be too lipophilic or too hydrophobic.   If it is too 
hydrophobic it will not be able to pass through the stratum cornea.   On the other hand, if the 
copper (II) complex is too lipophilic, it will become trapped in the underlying tissue.  
The ligand system in this study is based on a penta-cycloundecane amine derivative (Figure 1.2), 
which is a triene moiety linked to a rigid cage via an ethylene bridge.   The ligand system of the 
ON4 type is capable of donating four nitrogen atoms (i.e. secondary amine groups) to a metal ion 
centre.   The rigid cage structure on the ligand is expected to increase the lipophilicity and may 
also increase the stability of the metal complex by forcing the divalent metal into its favourable 
coordination geometry (see Figure 1.5) [2].    This is expected to drive the equilibrium towards 
complex formation [20, 21].  










Figure 1.2: Structure of PCU.homopiperazine (pentacycloudecane,-bis1, 2-1,4diazacycloheptane) 















 To develop novel copper based anti-inflammatory drugs that can be absorbed dermally. 
Objectives: 
1. Design a ligand which forms stable, labile copper complexes with high a level of 
specificity for copper binding and which is still able to diffuse across a lipid bilayer 
membrane (see Figure 1.2). 
2. Synthesis the designed ligand. 
3. Determine the protonation and complexation constants of PCU homopiperazine   against 





) over a pH range: 2-11. 
4.  Determine the structure of the metal complexes using NMR and UV/VIS spectroscopy 
studies. 
5. Verify these structures using computational studies (MM calculations). 
6. Calculate the in vivo speciation of copper using p.m.i/blood plasma model studies. 
7. Determine the dermal absorption of the copper (II) complex at physiological pH using a 
modified Franz cell, and to calculate their partition coefficients. 
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In the study of metal ion coordination equilibria in biological systems, the use of stability 
constants can readily provide a means of approximating the speciation of the metal ion of interest 
within the system [1].   The most widely used technique for the measurement of metal—complex 
stability constants is based on pH—metric titrations of a ligand in the absence and or in the 
presence of metal ions. 
Several experimental methods, including some spectroscopic techniques, can be utilized to 
investigate the chemical speciation occurring in solution.   Examples include ultra filtration, 
calorimetry, solvent extraction, potentiometry, reaction kinetics, nuclear magnetic resonance, 
Raman, UV/VIS and infrared spectroscopy [2].   From all these techniques mentioned above 
potentiometry is probably the oldest and most extensively used because of the easy availability of 
the electrodes, high sensitivity and reproducibility of experimental results, making it the most 
precise and accurate non-invasive technique available at present [2, 3]. 
 2.2 Complex formation 
The theory of complex formation and the potentiometric determination of stability constants have 
been dealt with extensively in literature [4].   Thus only a brief description of the reactions, 
equations and assumption that are applicable will be given here.  Interest in formation of metal 
complexes in aqueous solution has evolved from interpreting the mechanism of formation and 
correlating stability constant data, to numerous applied fields ranging from sewage treatment to 
designing of metal ion buffers for use in biological systems [5-6].   
Consider a general metal-ligand complex formation at equilibrium involving M, as a metal and L 
as a ligand.    
The stepwise formation of different complexes can be described by the following set of formation 
constants.   The charges are omitted for clarity.   
   M + L  ML                                   K1 = [ML]/ [M] [L]                        (2.2.1)          














   MLn-1 + HL  MLn + H                  Kn = [MLn] [H]/ [MLn-1] [HL]        (2.2.3) 
The equilibria represented by equations 2.2.1, 2.2.2 and 2.2.3 can also be expressed as overall 
formation constants, denoted by β, and these are given below [4-5]. 
   M + L  ML                            β1 = K1 = [ML]/ [M][L]                        (2.2.4) 
   M + 2L  ML2                        β2 = K1.K2 = [ML2]/ [M][L]
2
                (2.2.5) 
Thus, the stability constants in 2.2.4, 2.2.5 and 2.2.6 are related to the overall stability       




β = K                                                        (2.2.6) 
In any solution containing metal ions M, ligand and protons/hydroxyl ions H, a variety of 
complexes can be formed.   This phenomenon occurring in solution can be described by the 
following general equilibrium equation [4, 5, 6]. 
     pM + qL + rH  MpLqHr                                                (2.2.7) 
Where p, q and r are the stoichiometric coefficients for metal, ligand and proton respectively, 
while r = -1 refers to the proton being removed or the addition of a hydroxyl ion on the complex.   
Therefore this equation can take into account formation of mononuclear, binary, protonation or 
hydroxo, polynuclear as well as oligonuclear complexes [3].   However accurate determination of 
formation constants for this complex formed in aqueous solution is reported to be in terms of 
thermodynamic formation constant [2-6], and is defined as follows;  
T 






                                          (2.2.8) 
Were 
T
βpqr is the thermodynamic formation constant; and {} denotes the activities of the different 
chemical species participating in complex formation [4].   However, since activity of any 
chemical species in solution is given by the product of its concentration and activity coefficient 
(γ), for example {ML} = γML[ML] [4].   Therefore this equation for
 T
βpqr can be rewritten in terms 





















 *γi                                            (2.2.9) 
Were [M], [L] and [H] are the concentrations for metal, free ligand, proton respectively and γi 
quotient of activity coefficients respectively.   To avoid the complications involved in using or 
monitoring activities of different species in solution, thermodynamic formation constants are 
determined where possible in a solution of a background electrolyte at high ionic strength.   
Under these conditions, activity coefficient (γ) of an ion can be assumed to be constant [4-5].  
Therefore
 T 
βpqr can be expresed interms of concetration as follows: 
c 





r                                             
                 (2.2.10)  
Thus by applying the mass action equation, the concentration of any complex formed in solution 
at equilibrium is governed by the relative total concentration of each component taking part in its 














]                                            (2.2.11) 
Similarly the total ligand and proton concentration solution, TL and TH will be given by the 
following equation according to the law of mass balance;   






                                                 (2.2.12) 






                                                  (2.2.13) 
Where [M]p is the concentration of free aquated metal ions and the summation is over the 
concentration of all the metal containing species which may be protonated (r>0) or may not (r=0), 
while [L] and [H] represent the concentration of the uncomplexed ligand, proton respectively.  
In order to calculate the stability constants (βpqr ) from potentiometric data, the mass balance 
equations must be solved.   In these equations, the total component concentrations (i.e. TL, TM and 
TH) are known from the experimental procedure.   The unknowns include the β’s, free hydrogen 
ion concentration, free metal and free ligand concentrations, but the latter two physicochemical 














points and n.m.b.e mass balance equations at each point, then there will be a total of (np x n.m.b.e) 
free concentrations. 
 The position of equilibrium and hence the numerical value of the reported stability constant 
when expressed in concentration units is normally dependent upon the temperature and this is 
given by the van’t Hoff equation [3-7]: 
Log K = ∆H◦/RT
2
                                                                                        (2.2.14) 
Were: R =universal gas constant, T = absolute temperature and ∆H◦ is the standard enthalpy. 
Thus for exothermic reactions (i.e. -∆H◦) K decreases with temperature, conversely endothermic 
(i.e. +∆H◦) K increases with temperature [4, 5].  
.  
2.3 Glass Electrode Potentiometry (GEP) 
Virtually all equilibrium process taking place in aqueous solution involve hydrogen and hydroxyl 
ions whether directly or indirectly and therefore it is this ion’s activity which is measured in glass 
electrode potentiometric investigations [4].   Furthermore this has resulted in glass electrode 
potentiometry (GEP) having found its significant place in the investigation of many chemical 
systems in biological, medical and environmental studies [4-5].   GEP has been employed in this 
study (i.e. determination of stability constants) because of its linear Nernstian response, rapid 
reversibility and high sensitivity to aqueous hydrogen ions over a wide concentration range [5].   
However the accuracy of the results from (GEP) depends on the calibration procedure of the 
electrode employed in a particular study [5-7].   The measuring setup for potentiometric 
measurements always consist of two electrodes, a measuring or indicator electrode and a 
reference electrode.   For practical reasons these two electrodes are usually contained in a single 
combined glass probe/electrode; as illustrated by Figure 2.1 below. 
The reference electrode (usually Ag/AgCl) is an oxidation/reduction half cell of known and 
constant potential at a particular temperature, which is independent of the sample solution 














individual potentials from the reference Eref , indicator electrode Ein and liquid junction potential 
Eg. This is represented by the following equation; 
Ecell =  Ein + Eref + Eg 
 The potential measurement itself takes place virtually current free in the presence of a volt-meter, 
with a high impedance measuring input to avoid any potential drops during the analysis [5].  
Figure 2.1: schematic diagram of a combined pH glass electrode dipped in solution  
 
Where:  
U1: Galvani potential between measuring electrode and measuring solution  
U2: Galvani potential between internal buffer and glass membrane  
U3: Galvani potential between internal reference electrode and internal buffer  
U4: Galvani potential of reference electrode  
U5: Diffusion potential at the diaphragm 
 
The indicator electrode (in this case a pH glass electrode) produces a potential Ecell (relative to the 
inert reference electrode), which is dependent on the sample solution (i.e. is proportional to the 














The hydrogen ion activity is obtained from the emf reading of the glass electrode, following 
Nernst equation: 
 Ecell = Er + Ei + Eºg + RT/F *ln {H
+
}                                       (2.2.15) 
Where: Ecell= the measured emf of the cell 
Er = contribution arising from the reference electrode 
Ei = contribution arising from the liquid junction 
Eg = standard glass-electrode potential at unit activity 
R =universal gas constant 
T = absolute temperature 
F = Faraday constant 
{H} = hydrogen ion activity 
For the quantitative evaluation of data the Nernst equation is used to convert the experimental 
electromotive force values (E) into the equilibrium hydrogen ion concentration [H].   This is the 
case because the activity {H} of the hydrogen ion is defined as constant in solution with a 
constant ionic strength [4]. 
Ionic strength of a solution is defined by the following expression; 
  I = ½ ∑ Ci Zi       (2.2.16) 
Where Ci is the concentration of ionic species i and Zi is the charge on that ion.                                                                             
If the ionic strength is kept constant, the hydrogen ion activity can be expressed as a 
concentration, this concept of ionic strength was first introduced by Lewis and Randall in 1921, 
who stated that in a dilute solution, the activity coefficient of a given strong electrolyte is the 
same in all solutions of the same ionic strength [6] and equation 2.2.15 can be obtained by setting 
s (i.e. slope) = 2.303RT/F and collecting together all the constants as E const: 
         E cell = E const + slog [H]                                                  (2.2.17)  
Furthermore it is interesting to note that the slope (i.e. s) of the Nernst equation indicates the 














2.4 Factors affecting the stability constants of complexes 
Complex formation is defined as the association of two or more simple species, each capable of 
independent existence [3, 6].   Therefore as a result, many species may form in solution and only 
the stability constants of the major species formed are used to select/describe the chemical 
speciation occurring in solution [6]. 
 The strength of the complex formed in solution is better described in terms of the Pearson’s 
hard/soft-acid/base theory, HSAB,  in which an acid or base is classified as either hard or soft or 
intermediate between the two [6].   According to this theory a hard acid will prefer to bond to a 
hard base while a soft acid will prefer to bind to a soft base [6].   More recently it has been 
suggested that a steric component plays a major role in the observed HSAB behaviour in solution, 
in addition to the covalent and ionic contributions [5-6, 10]. 
 It is a fairly general observation that the equilibrium constants of analogous complexes involving 
divalent-metal ions Mn through Zn and ligands that contain nitrogen as donor atoms; examples 













is referred to as Irving-Williams order\series [6-7].   However there may be some alteration in the 
series, this is thought to be caused by a change in the electron distribution on the metal ion centre 
(i.e. high spin to low spin or vice versa) [7].   A stable complex is one with its ligands spread 
around the metal ion in such a way as to minimize repulsion.   Many metal ions also have bond 
directionality and in these special cases the positions of the ligand around the metal ions play a 
major role in the resulting complex stability [8].  
 
2.4.1. Chelate effect  
There is a pronounced increase in the formation constant of metal complexes containing a 
bidentate ligand as compared to monodentate ligand containing complexes [8-9].   This enhanced 














dependent on the size of chelate ring, with 5-membered and 6-membered chelate rings being the 
most stable, [4, 6-8].   It was also found that the stability of the complexes of divalent metals ions 
with the macrocyclic ligand is greater when compared to the complex with the analogous open-
chain ligands [6].   This phenomenon is referred to as the macrocyclic effect.   Perhaps the 
marked differerence between macro-cyclic ligands and open chain (chelating) ligands, is their 
selectivity for metal ions, based on the metal ion fitting perfectly (i.e. at optimal distance and 
geometry) from the donor groups in the cavity of ligand. This leads to two important factors 
which contribute to the stability of macrocyclic-metal complexes.   These are the preorganisation 
of macrocycle (enthalpy effect) and the size of the chelate rings (entropy effect). 
 In order to understand these two effects we must invoke two well known thermodynamic 
relationships: 
∆Gº = -R T logK                                                                                         (2.2.13) 
∆G◦ = ∆H◦ - T∆S◦                                                                                     (2.2.14) 
Where: ∆G◦ is the standard Gibbs free energy, R =universal gas constant, T = absolute 
temperature, ∆H◦ is the standard enthalpy and ∆S◦ is the standard entropy. 
These two parameters can be calculated by either using the Vant’ Hoff equation, or calorimetry, 
with the latter been favoured for practical reasons.   Enthalpy effects depend on bond strengths 
and entropy effects referrer to the changes in the order/disorder of the solution as a whole [6].   
Preorganization in macrocyclic ligands is based on a principle that the free ligand has less entropy 
relative to an open chain chelater because of its limited conformational states and hence the 
change in entropy upon metal ion coordination is less [8].   There is also an enthalpy contribution 
because, in a flexible ligand, the free ligand would need to adopt a higher energy conformational 
state before coordination can occur.   In the pre-organized ligand, this increased energy has been 
















2.5 Data analysis 
Even with the current development of highly non-invasive techniques for the determination of 
stability constants, considerable discrepancies continue to exist between the values published for 
the same chemical system by different authors [5-10].   This commonly occurring phenomenon 
was concluded as being associated with the computer analysis of the titration data employed by 
these researchers, the most likely source of error being ‘choosing the correct model’ to explain 
the chemical system [9].   In this study we have used the ESTA suit of programs to analyse the 
data.  
2.5.1 The ESTA (Equilibrium Simulation of Titration Analysis) Program Library. 
 
Computer analysis of equilibrium data has replaced the graphical methods used in the past, and 
many programs exits to analyse potentiometric data (Martell and Motekaitis, 1988).   One such 
program is ESTA, which was intended as a flexible tool for the determination of protonation and 
formation constants in aqueous chemical equilibria.   The program library is used to calculate 
equilibrium distributions of chemical species, to analyse potentiometric titration data and to 
manipulate titration data for a variety of other purposes.   The calculations are performed using a 
Gauss-Newton method to solve the mass balance equations (m.b.e) which were discussed in 
section 2.2. 
At each point of the titration the computer calculates the emf of the system and finds the 
difference between the calculated and the observed values.   The difference is then squared and 










 2                 
                              (2.3.1) 
Where 
N = total number of experimental titration points 
ne = total number of electrode (one in this study) 














Wni = weight of i
th
 residual at n
th
 point  
Yni = total concentration of electrode ion i or the electrode emf of electrode i, at the nth titration 
point. 
In order to minimize U, a gauss-Newton approach is employed and this assumes that the function 
is quadratic with respect to all the parameters.   Therefore U can be expressed as; 




H p)/2                                                                     (2.3.2) 
Where a and b, are the Gauss-Newton quadratic parameter vectors, p is the optimization 
parameter vector, p
t
 transpose of p and H, the Hessian, is given by: 
Hsr = d
2
U/dpspr                                                                           (2.3.3) 
A well defined system, with good initial estimates, often converges. Calculations are terminated if 
the shift vectors are large or if the shift vector has an upward gradient.   This indicates that there 
was something wrong with the input data and therefore the mass balance equation cannot be 
solved [3].  
Once U is sufficiently minimized, the standard deviation, the Hamilton R-factor and its limit are 
reported together with the optimised values of the stability constants.  
The Hamilton R-factor (R f) and the R-limit (Rlim) are calculated using the following formulae: 
R
f













]1/2                                                 (2.3.5) 
ESTA is also used to calculate two important functions from the titration data, and are explained 
below.  
2.5.2 The Formation Function (Z-bar) and Deprotonation Function (Q-bar) 
 
In the absence of a metal ion, the formation function (ZH) is expressed as; 
ZH = (T*H – H + OH)/ TL                                                            (2.3.6) 














OH = KW/ [H].   ZH can also be defined as the average number of hydrogen ions bound to the 
ligand at each pH reading.   The ZH is plotted against pH. 
In the presence of a metal ion, the formation function (ZM), is expressed by; 
ZM = (TL – [L])/TM                                                                  (2.3.7) 
Where TL and TM are the total concentration of the ligand and metal respectively, and [L] is the 
free-ligand concentration.   TL is given by equation 2.3.6. And also ZM is also plotted against pL 
or (-log [L]). 
However this definition of the complexation function (ZM), only applies to mononuclear binary 
complexes.   A plot of ZM-bar-log [L], gives a picture of the representative species in equilibria.   
If only simple, mononuclear, binary species are formed in solution, then the graphs determined 
from titrations performed at deferent initial ligand, and metal concentrations should overlap one 
another through the pH range of interest.   If this does not happen then this means that there are 
other species formed in solution.   The mysterious fanning back of the ZM-bar curves indicates the 
presence of hydroxo or mixed hydroxo species [7].   This behaviour by the graph can assist in 
choosing the correct model for description of an unknown chemical system and hence for the 
refinement process (discussed later, see section 2.6.5). 
The deprotonation function (Q-bar), is defined as the average number of protons released per 
metal ion upon complexation with the ligand, and is expressed as follows; 
QM = (TH* - TH)/TM                                                              (2.3.8) 
Where TH and TM are the total hydrogen ion and metal concentrations respectively 
TH* is the calculated total concentration of the protons that would be necessary to give rise to the 
observed pH if no complexation took place, is given by the following equation; 




                                   (2.3.9) 
Where, the summation is over all protonated ligand species. 
In a binary system, a formation function represents the number of protons that would be on the 














nH = (TH* - [H] + [OH])/TL                                               (2.3.10) 
The difference (r) between nH and Q-bar gives the number of protons on the metal complex. This 
can be represented as; 
r = (q x nH) – (QH x p)                                                        (2.3.11) 
Where, p and q are the stoichiometric coefficients of the metal and the ligand respectively. 
2.5.3 Data error analysis 
In any physical measurement, knowledge of the errors involved is important.   A typical example 
is thermodynamic data where good protononation and stability constants require minimal 
experimental errors on the part of the researcher.    Identification of experimental error can be 
done by studying a well known system for instrumentally generated errors, or by varying the 
reaction conditions for a particular system and observing its reproducibility. Random errors in the 
experimental data are reduced by an increase in the number of titrations and titration points.  
 
2.5.4. Weighting. 
Weighting is a very important part of analysing data for errors.   This is because, while the error 
maybe constant, the information content and hence importance of each data point is not.   By 
weighting each data point according to its informational content, the influence of experimental 
(random) error can be minimised.   There are many other benefits, including (a) a more practical 
approach for dealing with changes in conditions such as temperature and ionic strength and (b) a 
more objective method of reconciling the marked differences that often occur between published 
parameters from independent investigators, thus the data can aspire to both be critical and 
comprehensive [5].   Weighting is defined as the reciprocal of the variance of the residual 
between the real and the calculated and the weight(p) of the i
th
 residual at the n
th
 point is given by 
the following expression; 




























ni are the observed and calculated variables of q
th
 residual at nth point 




































Experimental    
2.6 Equipment 
All titrations were performed in an inert double-walled reaction vessel maintained at 25ºC by a 
steady flow of water from the thermo-stated water bath using a Metrohm 799 GPT Titrino 
equipped with automatic burette and a Metrohm combined glass electrode system (i.e. pH/mV 
meter).   The slope of the electrode system was calibrated in terms of hydrogen ion activity using 
buffer solutions of known pH’s and Econst was determined by strong acid - strong base titrations at 
25 ºC.   The 799 GPT Titrino is also further equipped with an internal data chip programmed for 
equilibrium aliquot titration and titration data recording, thus controls all the functions of the 
burette without the need of a computer.   The reaction medium was kept inert by a steady gas 
flow of pure humidified inert nitrogen gas.   The nitrogen gas was purified  before  going into the 
reaction vessel by bubbling it through different glass bottles containing, 50% potassium 
hydroxide to remove carbon dioxide, Fierser’s solution to remove oxygen, glass wool, distilled 
water and finally the gas is passed through a solution of background electrolyte solution of ionic 
strength 0.15 M NaCl. 
2.6.1 Preparation and standardisation of solution 
 All solutions were prepared with recrystallized NaCl (Fluka) as background electrolyte, at ionic 






in double glass boiled distilled water.  The water is double 
glass boiled to remove the trapped CO2 and is finally kept in a plastic container (polyethylene 
bottle) protected by a carbosorb (sodium carbonate pellets) or CO2 trap.   All reagents were 
commercially available and of analytical grade.   These were used without further purification.   
However PCU.homopiperazine was obtained from the University of KwaZulu Natal, in a yellow 
oil form. 
The solution of HCl was prepared to a concentration of 0.01 mol dm
-3
 from Merck ampoules 
(1.09959 – Titrisol) in sufficient sodium chloride to give the ionic strength of 0.15mol.dm
-3














solution was standardised against recrystallized sodium tetraborate decahydrate (borax) Na2B4O7 
.
10H2O. 
The solution of 0.0995 M NaOH was prepared under nitrogen atmosphere from Merck ampoules 
(1.09959-Titrisol).   The resulting solution was standardised with a primary standard Potassium 
hydrogen phthalate (KHP) which was dried over night in an oven set 110 ◦C before use.   NaOH 
solution was further standardised against 0.01 M HCl solutions. 
2.6.2 Preparation of Ligand solutions 
Stock solution of each ligand (i.e. homopiperazine and PCU.homopiperazine) was prepared to a 
concentration of 1.0 mM and 7.6 mM respectively.   Each ligand solution was prepared by 
accurately weighing the exact mass required of each in a 100ml volumetric flask and diluting to 
the mark with a standard solution of HCl.  Both ligand solutions were corrected for ionic strength 
by adding sufficient sodium chloride as background electrolyte.   Standardization of each ligand 
was performed by acid – base titrations according to Gran’s method [14, 15], 
 Addition of 0.01 M HCl resulted in the pH of the ligand solution dropping to a value of 2 and 
this was done in order to increase the solubility of ligand and to make sure that the ligand was 
fully protonated [15, 21]. 
 2.6.3. Preparation of metal solutions 
Standard solutions of divalent cations Cu(II) and Zn(II) were prepared from CuCl2.
 
2H2O, and 
ZnCl2 respectively and similarly as above, the solutions were corrected for ionic strength by 
adding background electrolyte.   Each metal solution was standardised by direct titration against 
0.01 M standard solution of disodium salt of ethylenediamine tetraacetic acid (Na2EDTA) using 
standard methods [13, 15].   Fast sulphon black F (FSB) and solochrome black (SB) were used as 




ions respectively.   Furthermore prior to the 
direct titration with Na2EDTA, all divalent metal ion stock solutions were purged overnight with 














subsequent metal hydroxide precipitation, which may lead to a the wrong metal concentration 




2.6.4. Equipment and Titration procedure 
Before any electrode calibration could be done the electrode was stored over night in a 0.01 
mol/dm
3
 HCl solution, this was done to improve the response of the electrode.   The slope of the 
glass electrode was calibrated for hydrogen ion activity with commercially available buffer 
solutions of known pH (i.e. 4, 7.02 and 9.18) done according to Vogel’s procedure [13].   The 
Nernstian slope was accepted if it fell in the range 58.60 — 59.16. 
The pKw (i.e. the dissociation constant of water), the Econst and slope (s) of the electrode were 
calibrated using an acid-base titration.   For a more precise data analysis of these electrode 
parameters, the titration data was imported into the ESTA file template. Furthermore only 
titration data in the pH region of 2.3-2.9 and between 10.8 and 11.3 were used.   This was done to 
reduce the effects caused by liquid junction potential, acid error and to minimize sodium errors 
found at high pH values respectively.   The electrode calibration using acid-base titration was 
performed to suit the conditions such as temperature (25ºC) and ionic strength (I= 0.15 mol/dm
3
) 
[15].   
The ligand protonation titrations were performed by directly weighing appropriate aliquots of the 
stock ligand solutions into the reaction vessel.   This solution was then titrated against the 
standardised NaOH solution introduced via piston burettes at preset volume increments into the 
titration cell maintained at 25 
º
C.   In one trial titration the (mV/pH v/s burette volume), data is 
recorded at each point (i.e. each volume increment) and is examined until equilibrium is reached.   
This together with accurate knowledge of base concentration, total acid concentration, pKw and 
electrode parameters (i.e. Econst and electrode slope), allows for the determination of protonation 
constants in ESTA (discussed later).   Addition of NaOH solution does not change the ionic 














polyamines, so each −NHx
+
 cation will be replaced by equivalent amounts of Na
+
 ions [5].   The 
same procedure was carried out for the metal-ligand complexometric titration but with initial 
varying concentrations ratio of the metal ion and ligand.   All solutions except the ligand (which 
was weighed) were introduced via piston burettes, read to precision of 0.03 ml.   All titrations 
were performed in duplicate, and were constantly stirred by a magnetic stirrer. 
The metal complex formation curves were obtained at 2:1 to 3:1 ligand to metals ratio. However 
for both Zn(II)–HP and Zn(II)-PCU-homo systems precipitated or the Zn(II)-hydroxide was 
formed as pH was increased >7.   This limited our analysis for stability constants for the Zn(II)-
PCU-homo complexes.  
2.6.5 Experimental Data Analysis 
 Data analysis was done with the help of ESTA (Equilibrium Simulation for Titration Analysis) 
computer library.   Prior to data analysis the guessed complex species and their stability constants 
were calculated using the task BETA of the ESTA program.   These were then entered into a 
preformatted ESTA data file for the determination of protonation constants and using task OBJE 
in the ESTA2A module, which gave out modified values of the stability constants.   The OBJE 
task was also used to optimize for the weak acid or ligand concentration describing the system.   
While for the determination of metal complex formation constant, the titration data was imported 
into a preformatted ESTA data file for the determination of metal complex stability constant 
which also contains metal hydrolysis constants obtained from data of Baes and Mesmer and 
Krateng at 25ºC which have been corrected for ionic strength I= 0.15 M [12].   Then the 
thermodynamic parameters (i.e. metal complex formation constants βpqr) were calculated the same 
way as protonation.  The reported formation constant results are based on a correct model 
determined using complex formation function (Z-bar) calculated in the ESTA1 module.   
Furthermore, from the experimental data the models were accepted as correct when the observed 
and calculated plots of ZH-bar, and ZM-bar overlapped each other respectively and output data 














graphs were obtained by substituting the final stability constants into the SPEC task in ESTA and 
the plots were obtained by using plot 1 option in SPEC. 
Task SPEC was then finally used to calculate the species distribution diagrams as a function of 
pH and further used as a criterion to check the validity of the model chosen to explain the system.   
The study of homopiperazine system was studied in order to check the experimental procedure.   
The results shown in table 2.1 were in good agreement with the values reported in literature for a 
similar system. 
2.7 Results and Discussion 
2.7.1 Protonation Constants 
The overall protonation constants (log βpqr) for the homopiperazine system were investigated in 
the pH range 2-11.   These protonation constants were confirmed by a complete overlap of the 
calculated (theoretical) and the observed ZH-bar curves, shown in Figure 2.2(a).   The values of 




Figure 2.2(a) protonation formation curve, ZH-bar plotted against pH for homopiperazine at 25º C 




). The different symbols in the graph represent titrations performed at different 
initial concentrations, and the solid line is the theoretical curve calculated using the model in 
Table 1.1. (b) Protonation species percentage distribution curves of homopiperazine 
([L]T=1.0mM) as a function of pH. 
(a)                                                                        (b) 
   






































Figure 2.2(a) shows the average number of protons on homopiperazine (HP), i.e. ZH-bar, as a 
function of pH.   The ZH-bar function rises and levels off on 1 (i.e. ZH-bar= 1) at pH 10.   This 
indicates that one amine group in the HP system is protonated.   Furthermore the ZH-bar function 
then rises again and plateaus when it reaches a value of 2 at pH 7, thus indicating the simple 
stepwise protonation of the second basic site.   This indicated that, there are 2 protons bound to 
the ligand, with pKa values of approximately 10 and 7 respectively.   The final refined 
equilibrium constant values with their corresponding standard errors are given in Table 1.   The 
agreement between the observed and calculated formation curves (see Figure 2.2(a)) and the low 
standard deviations in the refined pronotation constants give more confidence in the results (see 
Table 1). 
The calculated speciation diagrams (i.e. calculated for 1 mM solution) of homopiperazine based 
on the stability constants reported in Table 1.1, is shown in Figure 2.2(b).   From this diagram it is 
clear that, between pH’s 2 and 7.1, the LH2 species is
 
present as the dominant species, reaching 
approximately 98%.   LH only starts forming at pH 7.6, with the neutral species (i.e. free ligand 
[L]) only reaching significant amounts in solution when the pH>10. 







. S.dev denotes standard deviation in logβpqr; Rf
H
 is the Hamilton R-factor 
and RlimH its limit.  nt is the number of titration points. The general formula of a complex is 




p q r s.dev log β Rlim
H Rf
H nt Lit [18] 
HP-Hn
+
 0  1  1 0.002 10.21 0.01 0.008 136 10.26 
 0  1  2 0.003 17.09    16.6 
HP-Cu(II) 1  1  0 0.01  7.6   0.03 0.02 600 7.8 
 1  2  0 0.01 12.6    13.8 















The pKa values obtained for homopiperazine agree well with those from the literature (see Table 
1).   The pK1 of 1, 3-diazacyclohepane (homopiperazine) is 0.77 log units greater than that of a 
related derivative piperazine (pK1 9.44).   This phenomenon is believed to be caused by the 
positive inductive effect of the extra methylene group on homopiperazine.    
There is also a slight increase in the pK2 of HP due to the increased inter-nuclear distance 
between the two amines which results in less repulsion experienced between the two amino 
groups.   A similar trend of an increase in base strength brought about by methyl substitution is 
also reported by Golgberg et al. [16] in a series involving ethylenediamine and its substitution 
products, N-methylethylenediamine, N’N’’-dimethylethylenediamine, pK2 = 6.63, pK2 = 9.90; 
pK2 = 10.2 respectively.   The relatively low pK2 value for the second protonation site compared 
to the first (pK1) in HP is due to the columbic repulsion between the incoming proton and the 
proton already attached to the ligand [10-16].   Statistical factors must also play a role as the 
stability constants decrease with decreasing number of available binding sites on the ligand [6-8, 
14].   The pK1 of homopiperazine was observed to be 0.43 log units less than the pK1 (10.64) of 
methyl amine [10].   This is expected in moving from primary to secondary amines due to steric 
hindrance and solvation effects which are reported to override the positive inductive effects in 
molecules [10-15].   Furthermore pK1 of homopiperazine is quite similar to the pK1 10.16 
reported by E. Bianchini et al. [20] for a related secondary amine derivative N’, N’’-
diethylethylenediamine despite a different background electrolyte being used, thus giving further 



















2.7.1.3 Cu(II)-homopiperazine system  
The formation function (ZM-bar) and complex species percentage distribution curves of the 
Cu(II)-homopiperazine system are shown in Figures 2.3(a) and 2.3(b) respectively. 
The complex formation function, ZM-bar, measures the average number of ligands bound per 
metal ion.   This function is plotted against the negative logarithm of free ligand concentration 
(pL).   
   
Figure 2.3(a): formation function curve, ZM-bar against pL for homopiperazine at 25 ºC in 0.15 M 
NaCl. The symbols represent complexation curves for various metals to ligand ratios, [(▄) 1:1, 
(▲) 1:2 and (●) 1:3) and the theoretical curve is the solid line. (b) Complex species percentage 
distribution curves of homopiperazine-copper system (1:2 ratio) as a function of pH  
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Figure 2.3(a) shows the ZM-bar function for Cu(II)-homopiperazine system plotted against pL. At 
high pL (i.e. low free ligand concentration) or high pH the ZM-bar-function rises and slightly 
plateaus below 1.   This indicates the stepwise complexation of one ligand to a single divalent 
copper ion, therefore forming the ML species at pH 7.5.   As pL decreases, the curves rises again 
and plateaus at 1.7 at pL 4.7, thus indicating the attachment of the second ligand to the metal ion 














formation of a mononuclear complex as the major species formed in solution.   However, at 
higher pH the ZM-bar curves ‘fan-back’, thus indicating the formation/presence of a hydroxo 
species in solution.     
Analysis of the data yielded the model presented in Table 1.1.   An excellent agreement between 
the theoretical (i.e. solid line) and experimental complex formation curves in Figure 2.3(a) at 
different metal to ligand ratios further supported the model chosen in the data analysis.   The 
model showed a reasonably low R factor and relatively small standard deviations in the log βpqrs, 
thus giving confidence to the model chosen.   Comparing the formation constants (7.6) in Table 
1.1 for the ML species, with (β110 = 8.34) for (N, N’-dimethyltrimethylene-1, 3- diamine reported 
by T.A. Kaden et al. [8], it is interesting to note that HP forms a weaker complex with copper (II).   
However this is expected because of the weak base strength (i.e. low pKa values) exhibited by the 
amines in the homopiperazine system.   Furthermore in comparing the formation constant of 
homopiperazine with of N’, N’’-dimethylethylene-1, 3-diamine [17] (β110 = 9.95), the ML species 
of the latter is more stable than the ML species for copper (II)-HP system.   This is the case 
despite N’N’’-dimethylenethylene-1, 3-diamine having a slightly lower base strength.   Perhaps 
the reason for the weak complex might be from the ring strain in the case of homopiperazine (i.e. 
no freedom for rotation around the C-N-C bond in homopiperazine when compared to its linear 
analogue) [10].   Also the fact that homopiperazine forms 6, 5 membered chelate rings at the 
same time upon metal binding while in the case of N’N-dimethylethylene-1, 3-diamine only a 
single 5 membered chelate ring is formed may account for the weak complex strength.   
Comparing the equilibrium constants of ML (7.6) and ML2 (5) for HP-Cu (II) system, there is as 
considerable decrease in complex stability in moving from ML to ML2 and this is consistent with 
and can be attributed to steric crowding around the metal ion as more donor groups are involved 
in the formation of ML2 when compared to the two amines in ML species [14-17].   From the 
species distribution curve in Figure 2.3(b), calculated from the data in Table 1.1, it is clear that 














at higher pH values.   It is interesting to note, from Figures 2.3(b) that as the ratio of ligand: metal 
is increased the onset of MLH-1 formation is suppressed.   Furthermore ML2 is the dominant 



































2.7.2. PCU.homopiperazine system 
 
The formation and stability constants were evaluated using a similar procedure that was 
employed in the investigation of the HP system.  
 
2.7.2.1 Protonation constants 
 
The ligand PCU.homo possesses two secondary and two tertiary amines, so as expected, the 
ligand was able to take-up four protons (see Figure 2.4 (a)).   Table 2.2 contains the logarithm of 
the overall protonation constants for the studied ligand.   In the pH range of interest (2-11), 
PCU.homo presents two of its secondary amines as moderate to strong bases with the remaining 
amines behaving as weak bases.   This trend is consistent with many rep rted protonation 






























Figure 2.4(a): protonation formation curve, ZH-bar plotted against pH for PCU.homopiperazine at 
25 ºC in 0.15 M NaCl. The symbols represent titrations performed at different initial 
concentrations, while the solid theoretical line was calculated using the model given in Table 2. 
(b) Protonation species percentage distribution curves of PCU.Homopiperazine ([L]T=7.6mM) as 
a function of pH. 
 
(a)                                                                    (b) 
       




























          
 
Figure 2.4(a), shows the protonation function ( ZH-bar) as a function of pH.   At high pH (> 11) 
the curve is at zero (i.e ZH-bar = 0) indicating that the last proton is lost from the ligand, this is 
also confirmend in the species protonation distribution curve (see Figure 2.4(b) with L being 
dominant species at higher pH’s (> 10 ).   As the pH decreases, the Z-bar  rises again and levels 
slightly below 2 (i.e ZH-bar = 1.8) at pH 7, indicating that there are two protons added on the 
ligand.   Note there is no leveling off of the curve at Z-bar 1 indicating that pKa1 and pKa2 are 
very similar.   Between pH 7 and 5 the curve rises further and plateaus at a ZH-bar value of 4 















Analysis of the experimental data yielded the proposed model in Table 2, comprising of the 
following four species LH, LH2, LH3 and LH4 and these were then used to explain the protonation 
sequence.   From Figure 2.4(a)  the leveling off of the ZH-bar curve between pH 9 and 7 at 2, 
indicates that the di-protonated species LH2  will be dominant over the physiological pH range.  
This is cornfirmed by the calculated species distribution graph in Figure 2.4(b) which indicates 
the presence of LH2 as the dominant species in the physiological pH range of 7 to 9 reaching 
87%.    
Another interesting and noticeable feature in the graph is that the initial rise of the Z-bar function 
to a value of 2 indicates that two protons are added simultaneously (i.e. have similar pKa values) 
[20].   This trend has also been observed for related tetra-amine system, {3,7,15,19, 25, 26-
hexaazatricyclo[19.3.1.1]hexacosa-1(25),9,11,13(26),21,23-hexane} reported by Dhont et al. 
[21].    
 







S.dev denotes standard deviation in logβpqr; Rf
H
 is the Hamilton R-factor and Rlim
H
 its limit.  n is the  
number of titration points. The general formula of a complex is MpLqHr denoted by the 
stoichiometric coefficient pqr. 
 





 0  1  1 10.28 10.28 0.01 0.006 0.01 
  0  1  2 19.39 9.11 0.01     
  0  1  3 26.27 6.88 0.01     
  0  1  4 31.71 5.44 0.02     
 
Table (2) shows the protonation constants for PCU.homo together with their corresponding 
statistics.   A low R-factor further indicates the correctness of the protonation model chosen and 
thus increases the confidence in the values obtained experimentally.   It is interesting to note that 














suggesting that the cage structure has little effect on the pK1 of PCU.homo.   As can be noticed 
from the speciation diagram (i.e. Figure 2.4(b)), at the start of the titration LH4 is the dominant 
species at 95%, this also gave further support that the model chosen to describe the protonation 
sequence for the system of PCU.homo is correct.    
The difference in the pKa between pK1(10.28) and pK2 (9.11) is 1.17 log units, and this suggests 
that the binding of first and the second proton are independent of each other.   However this 
decrease in basicity, indicates that protonation of the second amine group is slightly more 
difficult.   This is thought to be as a result of repulsion between the incoming proton and the 
proton already attached to the ligand or this phenomenon can be explained as caused by a 
statistical factor following the well established thermodynamic fact that stability constants 
decrease with decreasing number of available binding sites.   Comparing the ∆pK1,2 in HP (i.e. 
∆pK1,2 = 7) and that of PCU.homo (i.e. ∆pK1,2 = 1.17), this implies that the first two protonation 
process in PCU.homo system is occurring on nitrogen atoms that are separated by at least four 
methylene groups and consequently, these two protons should be located at the terminal amines, 
and this is shown in the proposed protonation scheme (i.e. K1 and K2) in Figure 2.5 below.   
The two low protonation constants pK3 and pK4 (i.e. 6.88 and 5.44 respectively) correspond to the 
protonation of the tertiary amines connected to the rigid cage through an alkyl group.  
The difference in the pK3 and pK1 is 3.4 log units.   This decrease in the third pK3 is as a result of 
the electrostatic repulsion on the ligand caused by the two protons already bound to the terminal 
amines, thus introducing a negative inductive effect on the whole molecule [20, 21]. Furthermore 
pK3 (6.88) of PCU.homo is 0.18 log units lower than the pK3 (7.06) of PCU.EN (N, N’-bis 
[ethylene diamine]-4-[oxahexacyclododecane]) a related penta-cycloundecane derivative [21].   
This low pK3 value observed for PCU.homo relative to PCU.EN can be explained by solvation 
effects caused by the extra steric crowding around the tertiary amine.   This decrease in amine 
basicity has also been reported when a secondary amine is methylated [10].   It is interesting to 














amine of a related penta-cycloundecane ligand (PCUA), with pK1 = 10.26 and pK2 = 9.517 
respectively reported by Jackson et al.  This is because the primary amines in PCUA have their 
base strength weakened by the effect of the CONH group [20].    




















































2.7.2.3 Complex formation  
The stability constants were evaluated and confirmed in the same way as mentioned above in the 
pH range of interest 2-11 and results are listed in Table 2.2 below. 
2.7.2.3.1 Cu(II)-[PCU.homopiperazine] system 
Figure 2.6: (a) Formation function curve, ZM-bar against pL for PCU.homopiperazine-Cu(II) at 




).   The symbols represent complexation curves for various metals to 
ligand ratios, [(▄) 1:3, and (▲) 1:2, while the solid theoretical line was calculated using the 
model given in Table 2.1.   (b) Complex species percentage distribution curves of 
homopiperazine-copper system (1:2 ratios) as a function of pH.                                  
(a)                                                                   (b) 
           
                                                                
 
Figure 2.6 (a) shows the ZM-bar function for Cu(II)-PCU.homo system plotted against pL.   After 
the start of the titration (i.e. pL>15), the formation function rises and levels off at ZM-bar value of 
1.6, thus indicating that the mononuclear ML species is not the only dominant species formed in 
solution in the physiological pH range.   The different symbols used, represents different metal to 
ligand ratios.   At low pL values (i.e. pL< 5) the curves fan back, thus indicating the formation of 
hydroxo or mixed-hydroxo complex species in solution.   Excellent agreement between the 
theoretical and experimental complex formation curves at different metal to ligand ratios supports 
the potentiometric model chosen in data analysis.   From Table 2.2, the reported standard 
















equal to its limit and this indicates that the model chosen to investigate this system cannot be 
improved any further.  
Table 2.: logβpqr of PCU.homopiperazine-Cu(II) system determined at 25
o







). S. dev denotes standard deviation in logβpqr; Rf
H
 is the Hamilton R-factor and Rlim
H
 its limit.  
The general formula of a complex is MpLqHr denoted by the stoichiometric coefficient pqr. 
 






 2  1  1 21.22 0.03 0.02 0.02 
  1  1  1 17.60 0.03     
  1  1  0 9.25 0.02     
  1  1 -1 -1.39 0.03     
 
 
2.7.2.3.2 Structure discussion – Complexation 
An interesting feature about the speciation graph (Figure 2.6(b)) is that at the start of the titration 
M2LH is the dominant species at low pH values.   The ligand system in this study is based on two 
diene moieties linked to a rigid cage and these contain ethylene and propyle linkages.   Upon 
complexation the amines should lose a proton.  During this period the solution will be buffered 
and furthermore the rigid cage on PCU.homo should limit the number of conformations that the 
free ligand will have.   This is expected to drive the equilibrium towards complex formation.   
However in order to explain the observed complex stability, a series of structures have been 




















Figure 2.7: Schematic representation of proposed structures of various Cu(II)-PCU.homo species.   
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The proposed structures for the MLH species of the metal ion-ligand complex in the present study 
are given in Figure 2.7(b-d).   In 2.7 (b and c) the metal ion is coordinated to only one of the 4 
nitrogens, while one of the nitrogens on the other homopiperazine is still protonated.   However 
this structure is unlikely because, if we consider the equilibria: M + LH MLH, with an 
equilibrium constant of 7.3 (i.e. logβ111 –logβ011).   This value is too high for a monodentate 
coordination of the metal ion.   In fact this value is close to the equilibrium constant of ML of 
homopiperazine (logβ110 =7.6, see Table 1.1).   Because of the chelate effect it is also unlikely 
that only one of the nitrogens of the homopiperazine would coordinate to the metal ion [15-17].    
Similarly, if we consider M2LH to be formed by coordination of a second Cu(II) ion to the MLH 
species, a stepwise log equilibrium constant of 3.62 can be calculated fr m logβ211 – logβ111.  This 
is very close to logβ110 obtained for Cu(II)/methylamine which is 4.11 [10].   Therefore it was 
conclude that the second Cu(II) ion must be monodentately coordinated to the second 
homopiperazine moiety on PCU.homo.   Furthermore the equilibrium constant for M2LH is 2 
orders of magnitude less than the pK4 (5.44) of the free ligand.   This must be due to the presence 
of the metal ion, either through columbic repulsion or through a different nitrogen being 
protonated.   Therefore (a) was chosen as the most likely representation of the M2LH species.   
Assuming that structure (d) is correct for the MLH species, then formation of ML species occurs 
with a pKa of 8.35 (i.e. logβ111 – logβ110).   This deprotonation could happen on its own (structure 
e) or with simultaneous coordination of the metal ion.  
Since the equilibrium constant of the ML species is close to the pKa 9.11 of the terminal amine, 
therefore it will be safe to assume that the proton lost is from this amine upon coordination to the 
copper (II).   The Ka of ML (PCU.homo) is 0.75 log units higher than the logβ110 (7.6) of the ML 
for HP.   This suggests that the coordination geometry of the ML species involves more than two 
amines coordinated to the central metal ion.   Comparing the structures (f) and (g), both structures 
will be stabilized by the coordination of the third amine thus forming a [5, 13] and [5, 10] 














Structure (h) was eliminated based on the difference in stability constants between the ML 
species (β110 =9.25) of PCU.homo and the ML2 species of HP (β120 = 12.6) which is 3.35 log units, 
therefore it is unlikely that the complex structure of ML would involve all 4 amine donor groups 
being coordinated to the metal ion.  
Similarly (i) was also eliminated because the value of the equilibrium constant (Ka = 8.35) for the 
ML of PCU.homo lies between the equilibrium constant of the ML (log β110 = 7.6) and ML2 (log 
β120 = 12.6) for HP.   Therefore the coordination geometry of the ML species does not involve 4 
amines coordinated to the metal ion.   Furthermore the binding of oxygen in the axial position 
will further destabilize the complex, putting more strain on the complex.  
The overall order of the stability constants for ML species of the two related ligand system 
PCU.EN and PCU.homo is revealed to be  PCU.EN (4N donor)
 
[23]  > PCU.homo.   The low 
stability constants observed for the ML species for PCU.homo- copper (II) system can be 
attributed to the steric effect on the PCU.homo caused by the cyclic nature on the amine nitrogen 
in homopiperazine moiety. 
Deprotonation of ML with a pKa (logβ110 – logβ11-1) of 10.64 results in the formation of the MLH-
1 species.   This value is similar to the pK1 of [Cu(II) (H2O)6]
+2
 (10.65) assigned to the 
deprotonation of the axial water molecule reported by Jackson et al. [7].   Therefore the structure 






















2.7.2.4 Zn(II)-[PCU.homopiperazine] system 
The study of the solution chemistry of Zn(II)-PCU.homo system was complicated by the 
formation of a precipitate at pH 7.   Furthermore no metal ligand interaction was detected with 
different metal to ligand ratios used thus making the determination of stability constants of the 
various species that might form in solution for this system impossible using the glass electrode.   
It is worth mentioning that the same observation was noticed with the Zn(II)-HP system [14], this 
was concluded as being caused by the cyclic nature of the ligand ‘homopiperazine’ which is 
believed to find it difficult to form a tetrahedral geometry around zinc, and this leads to a weaker 
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3.1 NUCLEAR MAGNETIC RESONANCE 
3.1 Introduction 
In order to determine explicitly the structures of various species formed in solution a number of 
spectroscopic techniques can be utilized; these include NMR, Infrared, Raman or/and UV/VIS 
spectroscopy [1].   However the use of nuclear magnetic resonance (NMR) as an important tool in 
structure and reaction mechanism determinations in aqua has grown significantly over the past 
decade and recently its use has been extended to in full body imaging (MRI) [1-2].   Similarly the 
use of NMR to determine acid-base equilibrium protonation constants for substances of biological 
importance, particularly amine groups, has increased considerably in the past 3 decades.   NMR 
spectroscopy has an advantage over potentiometric titration, in that NMR can be used to estimate 
protonation constants of organic ligands directly from biological mediums of physiological 
importance such as blood plasma [2] and urine which contain other acid and bases in solution by 
following the chemical shift of nuclei of interest as a function of pH or pD.   However in this 
study NMR was used to determine the sequence of protonation of the four amine groups on 
PCU.homopiperazine in water as a function of pH and to elucidate the complex structure it forms 
when coordinated to Cu(II) ion.   This is done by observing the change in chemical shift of 
protons on neighbouring (i.e. alpha position relative to amine group) carbons as a result of a 
proton being attached to an amine group [3].   Similarly the presence and or coordination of the 
paramagnetic metal ion (i.e. Cu(II)) is expected to broaden and change the chemical shift arising 
from α protons [4, 5], thus giving a clue about the coordination mechanism between the ligand 
and metal ion and the structure of the complex formed in solution [5].   The change in chemical 
shifts of 
1
H spectra were analysed by plotting the ∆δ as a function of pH (see Figure 3.2).   The 
inflection point in the curve of change in chemical shift as a function of pH can be used to obtain 
















1 ml of PCU.homopiperazine solution (7.6mM) in D2O was freeze dried with a vacuum drier to 
remove excess water from the ligand.   The 
1
H NMR spectra were recorded on a Varian Unity 
Plus 400 MHz instrument.   The pH of the solution was measured using a micro-pH 2000 meter.   
The pH meter was then calibrated in terms of deuterium ion activity as follows [4]. 
pD= pH + 0.4 
For protonation and complexation titrations, no attempt was made to keep the ionic strength of 
the solution constant.  
For the protonation scan, 7.6mM stock solution of PCU.homopiperazine was prepared in a 1ml 
glass vial, by dissolving the solid ligand in 1 ml D2O and a few drops of tertiary butyl alcohol 
were added to serve as a reference signal.   The pD of the solution was adjusted by adding 
concentrated NaOD and DCl solutions. 
 The solution was then transferred into a 5 mm NMR tube for measurement of the 
1
H NMR 
spectrum.   After recording of the spectrum the solution was transferred back into the vial (with at 
least 95% recovery) and pD measured again.   Agreement of the pD values before and after 
measurement of the nmr spectrum was within 0.02 pD units.  A known volume of NaOD or DCl 
was then added and the sequence – (measure pD, →record spectra, → measure pD, →add base or 
acid) – repeated until pH 11 was reached. 
To obtain the 
1
H resonance spectra of the copper (II) complex, the freeze dried ligand was 
dissolved in 1ml of D2O to the same concentration as in the protonation experiments (7.6mM) 
and adjusted to approximately pH 5 using NaOD.   Tertiary butyl alcohol was used as an internal 
reference.   For each scan a 20 μl aliquot of copper solution was added until a two- fold excess of 

















3.3 Results and Discussion 
Figure 3.1(a) shows the 
1
H NMR spectrum for protonation of PCU.homopiperazine in D2O as a 
function of pH.    From Figure 3.1 (a) throughout the pH range 1.32 to 9.89 the 
1
H signals 
labelled a, b, c, d, e, and f all shift significantly up-field, while the 
1
H resonance signals labelled 
m, i, j and k remained constant.   As a result the latter signals were assigned to the the 
adamantane cage.(see Figure 3.1(b)).    At high pH, analysis of the spectra was complicated by 
the fact that the PCU.homopiperazine has chemically equivalent CH2 and CH groups, resulting in 




H COSY spectrum at pH 8 was used to unequivalently 
identify/assign the proton signals at 2.8 ppm and 3.2 ppm.  The 2D spectrum was also used to 
follow the chemical shift of the protons α to the terminal amines (i.e. a and\or c).   In Figure 
3.1(c), the multiplet signal at 2.1 ppm labelled peak d is correlated to two resonances at 2.8 ppm 
and 3.2 ppm, and hence these were assigned to protons e and c respectively.   A CH2 peak 
labelled ‘a’ on the 2D spectrum appearing as a doublet at 3.2 ppm has only one cross peak at 2.9 
ppm and this resonances is assigned to proton b.   Similarly a second CH2 peak labelled f at 3.3 
ppm has one cross peak at 2.2 ppm, which can then be assigned to proton g.    At the start of the 
titration, at low pH (i.e. ‘between’ 1.32 - 4.65) there is no observed change in the chemical shifts.   
This indicates that no proton is removed from the ligand and the ligand exists as a fully 























H NMR spectra of PCU.homopiperazine as a function of pH. Chemical shifts are 
given relative to tertiary butyl alcohol as an internal standard. (b) Structural formula of 




H correlated spectrum (COSY) of 
PCU.homopiperazine at pH = 8. Chemical shifts are given relative to tertiary butyl alcohol as an 




C Heteronuclear Correlation spectrum (HSQC) of 7.9952 mM 
PCU.Homopiperazine solution in D2O at pH = 8. 
(a)                                                                                                                                                                         
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Figure 3.2 Plot of change in 
1
H NMR chemical shift of PCU.homopiperazine as a function of pH. 
  
Figure 3.2 shows the plots of change in proton chemical shifts as a function of pH, where a, c and 
b, e, f refer to the chemical shift of the protons attached to carbons next to the secondary and 
tertiary amine groups respectively.   d refers to the proton attached to the carbon in the beta 
position in the homopiperazine (i.e. heterocyclic moiety on the ligand) see Figure 3.1(b).   From 
Figure 3.2, between pH 2-6 the 
1
H signals labelled b, e, and f are shifted significantly up-field , 
while the 
1
H signals labelled a, c and d remain fairly constant.   This suggests that the former 
signals are  close to  the site of protonation which must be the tertiary amines.   From this change 
in chemical shift plot, the micro-protonation constant of the tertiary amine is estimated to be 5.2, 
which is close to pKa4 obtained from potentiometry.   However the chemical shift for the signals a 
and b changes considerably in the pH range 7-10.   This is mainly attributed to the fact that the 
two protons a and b are closer to the amine groups where protonation takes place, thus indicating 
the protonation of the secondary amines.   Again approximate values for pK1,2 are estimated to be 
9 and 10.   This is in good agreement with the values obtained from potentiometric studies.  The 

















Figure 3.3 Protonation scheme for PCU.homopiperazine based on NMR experiments, the cage 


















































H spectra of the Cu(II)-PCU.homo system as a function of Cu(II) concentration are shown 
in Figure 3.4 (a).   Copper (II) is paramagnetic, so it is expected to cause the proton peaks near 
the metal ion to broaden and shift down field.   In Figure 3.4(b), the signals of a, c, and d broaden 
and shift downfield as the concentration of copper is increased. The rest of the signals remain 
almost unchanged.   This result suggests that complexation has taken place with only the 
secondary amines (either one or both) coordinated to the central metal ion.   From potentiometry, 
at this pH = 7.23, the MLH species is the dominant species.   Furthermore, in Figure 3.4(a) more 
amine groups are close to the copper (II) ion centre.  This is indicated by signals arising from 
protons (a, b, c, d, e, and f) which are attached to carbons closer to the amine groups broadening 
considerably and with signals a, c, and f almost disappearing as the concentration of the metal is 
increased further.  In this region of pH = 8.1, the ML species predominates.   However from close 
inspection of the 
1 
H spectrum, signals b and e do not broaden and shift to the same extend as the 
other signals, thus suggesting that the coordination geometry in ML species involves two 
secondary amines (i.e. the terminal amines) and one tertiary amine being coordinated to copper 
(II) with the other tertiary amine uncoordinated.   This is consistent with the result from 
potentiometry.   However the decision of how many amine groups are actually attached to the 
central metal ion is made more difficult by the fact that over the entire concentration range only 
single resonances for non-equivalent protons are observed, indicating that the ligand is in rapid 




























H NMR spectra for complexation of copper (II) with PCU.homopiperazine as a 
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4.1 UV-VISIBLE SPECTROSCOPY 
4.1.1 Introduction 
An obvious difference between certain compounds is their colour.   Examples include quinone 
which is yellow; chlorophyll that is green and copper (II) sulphate which is blue [1].   In this 
respect the human eye is functioning as a spectrometer analyzing the light reflected from the 
surface of a solid or passing through a liquid.   Electromagnetic radiation such as visible light is 
commonly treated as a wave phenomenon, characterized by a wavelength or frequency [2].   
Visible wavelengths cover a range from approximately 400 to 800 nm [1, 2]. Spectrophotometry 
uses the visible region of the electromagnetic spectrum to give an idea of the electronic 
microstructure of metal systems, by quantifying the amount of light abs rbed by the system [2].   
This is because the amount of light a transition metal species will absorb directly depends on type 
of metal ion, its oxidation state, electronic configuration of the metal and the type of ligands 
surrounding it [2, 3].   As a result spectrophotometry is used extensively in literature for the study 
of solution chemistry of transition metal ion complexes [3, 4].   This is due to the various colours 
that are observed for transition metal complexes, which are caused by electronic transition 
between energy levels, whose spacing corresponds to the wavelengths available in visible light 
[2, 3-5].  
4.1.2 Electronic Spectra of Metal Complex 
When a molecule absorbs light of a suitable frequency, it assumes an exited state in which some 
of its electrons occupy higher energy levels, which only differ from the parent molecule by the 
distribution of its electrons and thus contains new chemical properties such as a different structure 
and energy state [3-5].   These transitions are frequently referred to as d-d transitions because 
they involve molecular orbital that are characteristic of transition metals.   However the intensity 
of the absorption bands is governed by a series of selection rules [4].   Transitions that are 














ungerade to ungerade (u-u) respectively, because there is no change of parity [3-4].   Those 
transitions that are allowed according to Laporte include transitions between gerade to ungerade 
or vice versa.   This therefore means that all d-d transitions are forbidden.   However transitions 
can occur if the symmetry of the molecule is removed.   The bonds in transition metal complexes 
are not rigid but undergo vibration that temporarily changes the symmetry of the molecule [5].   
This distortion from a perfect octahedral geometry increases the transition probability and hence 
the intensity of the transition [5].   In a tetrahedral ligand field environment there is no centre of 
symmetry and therefore the orbital may acquire some p-orbital character, thus allowing the 
forbidden d-d transition to be partially allowed [5]. 
4.1.3 Electronic Spectra of Copper Complexes 
The chromophoric nature of the copper (II) ion is due to its low-lying d-orbitals [4, 6].   Many 
copper complexes absorb light in the visible region of (400-800 nm), and the characteristic d-d 
absorption band changes its absorbance maxima according to ligands around the metal ion centre 
[3-7].   The aqueous chemistry of copper is largely focused on copper (II) complexes because 
they are more stable than copper (I) complexes in aqueous solutions [4] and of course Cu(I), 
being d
10
 has no d-d transitions.   Tetragonal distorted copper (II) shows a single broad poorly 
resolved absorption band in the visible region [4].   This belongs to three absorption bands, 













CuSO4.5H2O and many copper (II) salts are blue, and this is because they absorb light in the 
regions between 540-800 nm [2-5].   The absorption spectrum of a copper (II) complex involving 
amine groups as a ligands, have been shown to be pH dependent [7]. As the pH increases the 
ligand becomes deprotonated and coordinates to the metal ion displacing coordinated water 














wavelength) [5-7].   This is extensively reported for copper (II) complexes with 6 waters as 
ligands, which normally shows an absorption maximum at 800 nm [4-6].   If the four water 
molecules in the equatorial position on metal ion were to be substituted with four ammonia 
ligands, this would cause the metal to shift its absorption maximum to around 600 nm [3-6].   
This shift can be explained, as being caused by the strong ligand field splitting of the nitrogen 
atoms.   However it has been recently reported that coordination on the axial position causes a red 
shift in the absorption maximum of the band [5-6].   This indicates that when the electronic nature 
of the central ion is known, it can therefore be used to suggest the nature or number of the ligands 
surrounding the metal ion [7] and thus give an approximation of the structure that is formed in 
solution [7-8].  
Most copper (II) complexes that have been studied have been found to have distorted octahedral 
structures, and this is as a consequence of the unfilled d-orbital configuration of d
9 
on the metal 






) configuration results in the uneven filling of the eg orbital which 
results in a well known phenomenon called Jahn-Teller distortion. Jahn-Teller distortion causes 
the two ligands placed at axial positions and trans to each other to move away from the central 
metal ion until such a state where their inter nuclear distance is greater than that of the four 
remaining ligands place at equatorial positions [4].   At this stage the complex is said to have 
tetragonally distorted geometry [3-5].   Looking at the electronic distribution of copper (II) d
9
, 
one would expect copper (II) to have only one absorbance peak, but because of the Jahn-Teller 
distortion the degeneracy of the electronic energy levels is lifted.   This results in a shoulder on 
the expected absorbance peak [6].   Cu(II) ions have been found to form complexes with 
polydentate ligands with nitrogen as a coordinating atom and the resultant structures were found 

















4.1.4 Data Analysis 
Since the amount of light absorbed by a medium is directly dependent on the number of 
absorbing species within that medium, (A) absorbance can be used to estimate the concentration 
of the participating species in solution [7, 8]. 
This is because the amount of light absorbed by a system can be related to the concentration of its 
absorbing species using the Beer-Lambert Law, given by; 
 
                 A = log I0 / I = ε c l                                                              (4.1.1) 
 Where: c is the species concentration in mol.dm
-3
, 
           ε is the molar absorptivity and  
           l is the optical path length.  
           I0 is the intensity of incident ray 
           I is the intensity of the emergent ray  
For a solution of known species concentration and a given path length, the absorbance is 
dependent on the specific molar absorptivity coefficient of the species of interest [2, 3, 8-10]. For 
electronic absorption spectra of solutions containing more than one absorbing species at a 
particular wavelength the Beer-Lambert law can be expanded to give a linear combination of 
terms for each individual species [7-10], Equation 4.1.1 
A
λ




c2 + …. + εi
λ 
ci) = l∑ εi
λ
ci                                       (4.1.2) 
Where: A
λ
 = Absorption at wavelength (λ nm) 
εi
 λ









ci = concentration of the i
th
 the species (mol.dm
-3
)  
l    = cell path length (cm). 
Therefore if a certain species has a value of ε
λ 
equal to zero, then it does not absorb in the chosen 
















Billo has developed a simple empirical method which can be used to calculate the total electronic 
transition energy contribution from donor atoms in the coordination sphere of the metal ion [9].   
This is given by the following: 
Vcalc = ∑ Vi 
Where: Vi is the energy contribution of each donor atom, see Table 3.1. 
Table 3.1: Energy contributions to the coordination sphere of some donor atoms as proposed by 
Billo for a system involving Cu(II). 
Donor atoms/groups Energy contribution (cm
-1
) 
Amide  4.85 ± 0.04 x 10
3 
Amine  4.53 ± 0.07 x 10
3 
Carbonyl oxygen, H2O, OH
-
 3.01 ± 0.03 x 10
3 
Carboxylate oxygen atom 3.42 ± 0.10 x 10
3 
Oxime nitrogen 3.38 x 10
3 
 
Furthermore the nature of electronic transitions that are brought about by a chelating ligand can 
be inferred from general observation of the effect of monodentate ligands on the ligand field 
parameter [10].   Table 3.2 shows a guideline that is normally used for the estimation of the effect 
of the ligand field imposed by nitrogen based donor ligands [11]. 
























Spectrophotometric titrations were performed for Cu(II) complexation with 
PCU.homopiperazine.   These solutions were prepared in the same way as the solutions used to 
determine formation constant using potentiometry.   An aqueous solution containing 1:2 metals to 
ligand ratio was prepared in a quartz corvette of 1 cm length and the complex spectra were 
measured over the pH range 4-10.   Small amounts of 0.0995 M NaOH were used to adjust the 
pH of the solution.   The pH of the solution was monitored using a micro-pH 2000 meter.   Before 
any pH measurement could be done, the micro-pH 2000 was calibrated with commercial 
standards of known pH values (i.e. 4.00, 6.78 and 9) at 25ºC.   The calibration procedure was 
repeated every time after the solution’s pH change by 2 units.   The solution was kept at a 
temperature of 25˚C and the titration was allowed to proceed under a nitrogen gas flow.   
Spectrophotometric measurements were recorded  using a Hewllet Packard 8452 A Diode Array 


























4.1.6 Results and discussion 
The PCU.homopiperazine ligand system is an ON4 type ligand capable of donating four nitrogen 
atoms (amine groups).  The ligand also has ether oxygen capable of coordinating to a metal ion.   
During the pH titration, the solution of PCU.homo-Cu(II) showed a colour change from blue to 
violet as the pH was increased and this was concluded as being the effect of change in speciation 
in the solution as a result of coordination of different aza-donor atoms to Cu(II) ion [8].   This 
further meant a change in the absorption maxima of the solution’s dominant species [8].   In order 
to gain some insight into the coordination geometries of the different species in solution, their 
individual spectra were calculated from the total absorbance.  The deconvulation of the UV/Vis 
data [9] was performed using the UV-SPEC program.  Absorption spectra obtained in the pH 
range 4.4-10.6 are shown in Figure 4.1(a) and the deconvoluted spectra in 4.1(b) respectively. 
 
Figure 4.1(a) Absorption Electronic spectra of Cu(II) and PCU.homo in solution in the 
wavelength range 300-800 as a function of pH. (b) Deconvoluted electronic spectra of solution of 
Cu(II) - PCU.Homo system as a function of wavelength. 
 
 
Figure 4.1(a) shows the electronic spectra of Cu(II) and PCU.homo in solution in the wavelength 
range 300-800nm as a function of pH and Figure 4.1(b) shows a graph of molar absorption 





























The broad absorption bands observed in Figure 4.1(b) corresponds to the three overlapping, spin 















 tetragonally distorted Cu(II) complexes [14].   In the deconvolution, each wavelength is 
treated independently so the smoothness of the resultant deconvoluted spectra lends confidence to 
the spectra obtained and the model used to explain the PCU.homo-Cu(II) system.   As can be seen 
from Figure 4.1(a), at pH 4.5, there is no complexation taking place and this is indicated by a 
band with an absorption maximum of 790 nm, which corresponds to the absorbance maximum of 
the free hydrated copper species (i.e. [Cu(II) (H2O)6]
+2
) [8, 9, 10].     As the pH of solution is 
increased the absorbance of the solution increases and shifts to shorter wavelength as the pH is 
increased between pH’s 4.8 and 6, this is caused by coordination of the some amine groups to the 
Cu(II) ion.   The MLH species, with maximum wavelength of 650 nm and a molar extinction 






, is the dominant species in the pH range 4.8-6.0 (see 
potentiometric results Section 2). 
A further increase in the pH from 6 to 10 caused the absorption band to shift to a shorter 
wavelength (i.e. 600 nm) and there is also an increase in the intensity of the absorption band.   
This extra intensity of the absorption band is caused by increase distortion of the metal 
coordination geometry resulting from the binding of more nitrogen donor groups to the metal ion 
centre (i.e. Cu(II) ion).   From potentiometry speciation (Section 2, see Figure 2.3(b)), ML is the 







.   At pH’s > 10, no further change in the absorbance band could be observed 
indicating the ending of complexation or no change in the ligand field of the metal ion.   From the 
speciation results, the MLH-1 species should predominate in this region.    Hence it was concluded 
that max and ε are the same for both ML and MLH-1 species.    The absence of an isosbestic point 
in the absorption band in this pH range, further confirms that the structure of different complex 
(i.e. MLH, ML and MLH-1 species) being formed in solution as a function of pH are not different 














conformational changes when moving from one species to the next.   According to Billo, water 
has the same crystal field effect as OH
-
. 
4.1.7 Discussion and Structure determination 
The value of the molar extinction coefficient (ε) was observed to increase as the pH of the 
solution was increased in this experiment, while λmax remained fairly constant.   As can be seen 
from the above Figure 4.1(a) complexation in this system begins above pH 5 with the formation 







.   Figure 4.2 (a-c) shows various proposed possible structures for the 
different species, together with their theoretical (λmax) calculated using Billo’s method.   From 
Table 4.3 we see that the λmax observed for the MLH agrees fairly well with the λmax value (i.e. 
663 nm) calculated according Billo’s method for two amines bound to the central metal ion 
(structure a) and to the reported λmax (i.e. 680 nm) for the [Cu(II)(NH3)2(H2O)4] species in Table 
3.2 [11].   This further supports the proposed model that two amine groups are involved in 
coordination to Cu(II) in the MLH species.   This is consistent with the conclusion from 
potentiometry.
 






 and this 
λmax value is close to that predicted for structures 4.2b and c using Billo’s method.   However this 
value is less than that of the λmax [Cu(II)(NH3)3(H2O)3] species which is 645 nm [11].   A similar 
observation was noted by Linder et al. for the tri-dentate complex of N, N-bis[2-
(diethylamino)ethyl]-ethanediamine (i.e. moving from ML to MLH-1) [12].   This conclusion is 
consistent with the assumption from potentiometry, which states that the ML species is formed by 
the coordination of three amine groups to the central metal ion.   Furthermore the λmax values 
obtained for the ML species is characteristic of equatorial coordination of amines [10].   The 
hydroxo species was not detected, because MLH-1 only starts to reach significant amounts at pH 
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Figure 4.2: Proposed structures for the different copper (II) complexes species with 
PCU.Homopiperazine with their respective wavelength max, predicted using Billo’s method.   
The cage moety on PCU.homo is omitted for clarity: 
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4.2 MOLECULAR MECHANICS CALCULATIONS (MM)  
4.2.1 Introduction 
The accurate use of UV/VIS spectrophotometry or if possible X-ray crystal structure can readily 
predict the structures of the copper (II) complex formed/present in solution and solid respectively 
with high accuracy [9].   However in order to gain more knowledge about the energies involved 
in the formation of the different metal ion complexes, molecular mechanics can be used.   
Molecular Mechanics (MM) is a tool used to calculate the strain energy introduced into a ligand 
by virtue of its adopted coordination geometry around a metal ion [9, 14].   These calculations of 
the internal strain energy of a molecule are done using force fields, but the choice of which force 
fields to use in a calculation is entirely dependent on the type of complex or molecule (i.e. 
organic or inorganic) of interest and the software program used to run the simulation [10, 12].   In 
a typical MM calculation each atom in the molecule is treated as an individual particle.   Each 
particle is assigned a radius (typically the van der Waals radius), polarizability, and a constant net 
charge (generally derived from quantum calculations and/or experiment) [17].   Finally bonded 
interactions are treated as "springs" with an equilibrium distance equal to the experimental or 
calculated bond length and these calculations are shown in Figure 4.3 [17, 18].   The bond lengths 
and angles obey Hooke’s law, while other interactions occurring in the complex are calculated 
using Lennard-Jones potentials.   Some examples include dihedral angles and their equations are 
given in Figure 4.3.    Molecular mechanics was used in this study to determine the lowest energy 
conformation for the metal complex species of interest and therefore account for the order of 
stability of the various Cu(II)-PCU.homo complexes formed in solution (i.e. M2LH< MLH> ML) 
[13].   There are a limited number of reliable force fields to use for the MM calculation involving 
metal ions.  Therefore MM calculations involving transition metal ions are not done to the same 
















Figure 4.3: force fields, which are used in this calculation, contain the energy terms listed below 
[Brooks et al., 1983]: 
Internal energy terms: 
Bonds: Eb = ∑ kb(r – ro)
2
                    Bond Angles : Eø = ∑ k(ø -øø)
2
 
Dihedrals: EӨ = ∑ kӨ - kӨcos (nӨ) 
Non-bonded interactions: 











Electrostatic: Eel = ∑ qiqj/4πε0rij 
Where: r, Ө, ø, and rij are bond length, bond angle, dihedral angle and inter-nuclear distance 
respectively. Therefore the full internal energy expression can be summarized as: 
∑Utotal = (Eb + Eø + Eø + EvdW + Eel) 
 
However the MM calculations of internal strain energy does not take into account two important 
energy quantities which contribute towards complex stability involved in the coordination of 
copper (II) in solution.   These are entropy changes/chelate effect and electronic energy through 
ligand field stabilization energy.   For Cu(II) Jahn-Teller distortion is rarely included in the force 
field. 
In this study MM calculations the esff force field was used.   The different chemical species in 
solution were constructed using the BUILD module of the Accelrys Biosym/MSI software 
package and were based on the speciation models obtained from UV/Vis spectroscopy and 




















Figure 4.4: Possible conformations for the different species formed by the Cu (II)-
PCU.homopiperazine calculated using Insight (II). Table 4.4 lists the different contributions to 
the strain energy. 
MLH 
                        






                 
 
















         ML                                       
 
     
                                                  (c) 
    
              
                             
 
                                                                  
 
 
                                                     (d)                                                














4.2.2. Results and Discussion  
Figure 4.4 shows the different proposed species present in solution.   The internal energies of the 
possible structures for the different metal complexes were calculated using the esff force field, 
reported in Table 3.4 [11].   Structures a, and b are the two possible coordination geometries for 
the MLH species, with total potential energy of 113.15 kcal mol
-1
and 163.54 kcal mol
-1
 
respectively.  In structure ‘b’, three amine groups are coordinated to the metal ion.   These include 
one terminal amine, with the other terminal amine still protonated and both tertiary amines bound 
to the metal ion.   In ‘a’ only one side of the ligand is involved in coordination.   Comparing the 
change in internal energies given in Table 4.4, for structures ‘a’ and ‘b’, structure ‘a’ was chosen 
as the most likely representative structure for the MLH species and this is consistent with the 
structure proposed from UV/Vis spectroscopy.   The large energy contribution to the total internal 
energy in structure ‘b’ was due to the large bond deformation energy and the relative high torsion 
energy, which is believed to be caused by the ligand when coordinating to the metal ion because 
of the cyclic nature of the ligand moiety.   The ML species is believed to be formed from the 
coordination of more amine groups around the metal ion.   This species is present in significant 
amounts at pH’s > 8, therefore we expect that all amines are either coordinated to the central 
metal ion or they are deprotonated.  The representative structures for the ML species are shown in 
Figure 4.3 (c-d) with their corresponding energies given in Table 3.4.   Structure ‘c’ has an 
internal energy of 143 kcal mol
-1
, and its coordination geometry is proposed to involve three 
amines groups coordinated to the Cu(II) ion.  However, in the alternative structure ‘d’, all four 
amines are coordinated to the metal ion forming 2 highly strained five membered contiguous 
chelate rings and a ten member ring (i.e. a [5, 10, 5]) system with an internal energy of 211.73 
kcal mol
-1
).  Based on the MM calculations it seems that PCU.homopiperazine is not a 
tetradentate ligand, but behaving as a tridentate ligand.   This structure is consistent with the 














Table 3.4. The total internal energy (Eint), bond, angle bending (angles), bond twisting (tortion) 
and out of plane (Oop) distortion energies (kcalmol
-1



















Species Bond Angle Torsion Total energy Change in internal 





4.29 42.36 30.79 77.44  
[MLH] (a) 15.20 62.25 35.68 113.15 35.70 
[MLH] (b) 38.92 88.28 36.33 163.54 86.09 
[ML] (c) 11.12 94.40 42.35 147.90 70.45 
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5.1 In vivo modelling 
5.1.1 Introduction  
The nutritional and pharmacological activity of trace metals has been reported extensively in the 
literature [1].   It has also been well demonstrated that Cu(II) complexes are effective in treating 
inflammation associated with rheumatoid arthritis and this pharmacological effect was first 
associated with the free labile copper (II) concentration in the body by Sorenson et al. in 1976.   
In human blood plasma and other biological media, copper (II) ion is  present with its majority 
fraction irreversibly incorporated into metalloproteins, reversibly bound to, human serum 
albumin, with the remaining fraction of the metal ions bond loosely to low molecular mass 
ligands (e.g. carbonates, sulphates, phosphates, amino acids) or existing to a very small extend as 
free metal ions  [2].   These l.m.w complexes are believed to exist in equilibrium with other 
similar free l.m.w ligands and this multicomponent system exists in constant competition for free 
metal ion in the blood plasma and therefore control the biological potential of the metal in vivo [2, 
3].   L.m.w complexes are thought to have numerous biological roles, this includes being (i), 
involved as intermediates in some metal transport process; (ii) l.m.w complexes are also involved 
in the transportation of metal ion between cells in the body; (iii) or they may be required to keep 
certain metal in solution until the metal is needed by the body [2].   As a consequence, free metal 
ion or its aqua complex exists at very low concentrations.   This presents researchers in this field 
with two problems in measuring the concentration of free metal in solution, (i) since its 
concentration is very low it cannot be measured using current conventional analytical methods.   
Also due to the very large number of ligands (i.e. proteins) and other metal complexes present in 
blood plasma it is difficult to separate the components using modern separation methods [2].   
Furthermore, the use of probes to monitor equilibrium concentration might disrupt the equilibria 
that are being monitored.   Based on the reasons discussed above it is not surprising how the use 














plasma model was developed by May et al. and has been successfully used to account for several 
processes in drug therapy [3].   The blood plasma data base consist of seven metal ions, forty 
ligands, 250 published mononuclear binary constants measured under physiological conditions, 
with another 400 measured under non-physiological condition and 100 ternary complex 
constants.   Most complexes of blood plasma are charged and therefore need a neutral transport 
molecule that will help them cross the lipid bilayer found in cell membranes.   The May model 
uses a program called ECCLES (Evaluation of Constituent Concentrations in Large Equilibrium 
Systems) to execute its calculation.   ECCLES calculates the plasma mobilising index, which 
refers to the extend to which a particular ligand can mobilize a specific metal in the plasma 
without disrupting other metals ions present in blood or disrupting the equilibrium that is found to 
exist in the body [3].   
    
The ligands investigated in this study have been shown to form more stable complexes with 
Cu(II), than with Zn(II), but this does not mean that the ligands will bind copper selectively in 
vivo.   As a result modelling studies are necessary to enable us to study how PCU.homopiperazine 
will compete in the body system against other ligands [4].   In order to determine the efficiency of 
our ligands in mobilizing copper in vivo, the plasma mobilizing index of these ligands was 
investigated by using the plasma modelling program ECCLES [3, 4].  
5.1.2 The plasma mobilizing index (P.M.I)  
Plasma mobilizing index (p.m.i) is the ability of a specific ligand to increase the l.m.w. 
concentration of a specific metal in vivo.   P.m.i is given by the following expression: 
p.m.i. = (total concentration of l.m.w metal ion complexes in the presence of the drug) / (total 
concentration of l.m.w metal ion complexes in normal plasma) 
The log p.m.i is normally plotted against the log of the concentration of the ligand.   Therefore a 














ligand is a very good competitor against other potential ligands present in the blood plasma for 
the metal ion of interest [2]. 
Blood-plasma modelling was carried out by incorporating the formation constants determined in 
this study into the blood plasma model and this large database was then interrogated by ECCLES 
to determine the p.m.i as a function of ligand concentration [1, 3].  
Zn(II) was not included in the model because it was found not to coordinate to PCU.homo
 
 The 
results are shown in Figure 5.1 
 
Figure 5.1(a). P.m.i curve for PCU.homopiperazine and homopiperazine in blood plasma at pH 
7.43. (b) p.m.i curve calculated for different ligands in blood plasma. 
(a)                                                                         (b) 
                       
 
Figure 5.1(a) shows the p.m.i curves for Cu (II) plotted against the log [PCU.homopiperazine] 
and [homopiperazine] respectively.   Figure 5.1(b) shows the log p.m.i curves as a function of log 
[LIGANDS] for a series of related ligands.   As can be noticed from Figure 5.1(a) the p.m.i curve 
for PCU.homo runs slightly on top of the HP curve, thus indicating an increased p.m.i activity for 
the PCU.homo system.   Thi is a consequence of the increase in the complex stability observed in 
moving from homopiperazine to PCU.homo.   Another reason for the increased p.m.i value for 
PCU.homo over the HP system, might be the increased donor power (i.e. increased pKa values for 
the amine groups) observed for PCU.homo.   However PCU.homo mobilizes copper (II) to a 






















Figure 5.1(b)), with its Cu(II) p.m.i curve rising above 1 with 10
-2
 M ligand concentration used.    
This means that despite PCU.homo being highly selective for Cu(II) coordination in aqua 
solution, it is not good enough in mobilizing copper (II) in vivo, and the reason for this may be 
due to the fact that PCU.homo forms weak complexes with copper (II) when compared to the 
other related penta-cycloundecane derivatives, see Figure 5.1 (b). 
 
From Figure 5.1(b) we are able to see that PCU.EN (N-4-donor) N, N’-bis [ethylene diamine]-4-
[oxahexacyclododecane] and PCUA (N-4 donor)  3.5-bis [ethanediamine]-4-
[oxahexacyclododecane], are 6 and 3 orders of magnitude better at mobilizing Cu(II) in vivo than 
PCU.homo (N3-donor) respectively [2].   Therefore PCU.homopiperazine cannot be used 


































Low levels of bio-available copper in the blood have been associated with the development of 
chronic inflammation and with remission of symptoms seen with the administration of exogenous 
copper supplements [5, 6].   The use of copper bangle to suppress inflammation associated with 
RA has been known for a very long-time [5].   Walker et al. have measured the dermal absorption 
from these bracelets and found it to be significant [5].   Since then a considerable volume of 
literature addressing skin absorption of metal-based chemicals as the key to the observed 
beneficial biochemical and pharmaceutical activity has been reported [6].   Despite previous 
successful designs of various useful copper chelating agents capable of enhancing bio-availability 
of copper in the blood, the challenge still remains to develop a system which can enhance 
exogenous dermal absorption for topical application of copper (II)-based drugs because so far the 
current therapy for inflammation disorder rely on intra-articular or intravenous drug injection 
which causes the patient discomfort [7]. 
The stratum corneam is the major barrier to many potential diffusing chemical species that come 
in contact with the skin [8].   This is because the stratum corneam has a heterogeneneous 
multicomponent liphophilic membrane structure; which does not allow charged species or 
hydrophilic compounds to pass through it [8].   However, a well established fact is that 
hydrophobic species can pass through a lipid membrane.   Solomon et al. have shown that the use 
of neutral complexes of copper-dihistidine increases the absorption of copper in cells of children 
with menkes disease with the copper complex administered intravenously [9].  Furthermore 
Jackson et al. have also shown that incorporating hydrophobic groups on the ligand significantly 
enhances the absorption of copper complexes across lipid-membranes and the subsequent 














bonding or non-covalent interaction with the skin proteins will have an effect on the passage of 
chemical species through the stratum corneam [10, 11, 17]. 
5.2.2 Diffusion  
The mechanism by which chemicals passively diffuse across a lipid-membrane and the rate of 
passage is described by Ficks law [11, 14], 
 J = dM/S.dt.  
Where J is flux in g/cm
2
, S = cross section of barrier in cm
2
 and dM/dt = rate of diffusion in g/s.  
The flux which is defined as the amount of substance that passes through a porous membrane 
from region of high concentration to low concentration per unit time is related to the 
concentration gradient dC/dX (the driving force for passive diffuse) by the a proportionality 
constant, the diffusion coefficient D, and is given by the following equation : 
J = -D .dC/dX 
Where D = diffusion coefficient of a drug; C = concentration of drug in g/cm
3
; X = distance in 
centimetres of movement perpendicular to the sur ace of the barrier. Furthermore dC/dX is 
equivalent to (COUT – CIN) where COUT and CIN are the substrate concentration inside and outside 
the cell.   Therefore, when the concentration outside the cell is larger than inside the cell the 
concentration gradient dC/dX will be positive and the net movement will be into the cell. 
The relation between the permeability coefficient (Kp) and the steady-state flux is calculated 
according to following equation: 
KP = J/Ci 
Where Ci is the initial substrate concentration outside the cell and J is the flux.  Since the 
permeability coefficient (Kp) is in generally a physical property of the diffusing substrates, it is 
depends on physiochemical parameters, such as solvent temperature, solvent viscosity, nature of 
substrate and mass of substrate.   When expressed as depth of diffusion per unit of time (here in 














Therefore it is not surprising that permeability coefficient Kp is the best descriptor of membrane 
penetration of many cosmetic drugs [11-13]. 
 
5.2.3 Franz cell 
The primary objective of in vitro dermal absorption studies is to evaluate the rate of dermal 
penetration or to predict the percentage of dermal absorption of an administered dose of a drug of 
interest [12].   This type of in vitro dermal absorption study has been reported to provide key 
insights into the relationship between skin, drug and formulation, thus resulting in the 
development of safe new novel drugs [12].   However to date there is little or no data involving a 
quantitative study of the bioavailability of copper using human skin in vivo [12- 13].   The major 
research methodology used in skin permeation studies is the Franz diffusion cell. The model is 
based on a vertical diffusion of a drug between a donor phase and acceptor phase with a 
membrane (i.e. used to model the stratum corneam) mounted between the two compartments [12].   
The acceptor phase is maintained at a constant temperature of 37 ºC by circulating water from a 
thermostated water bath.   The disadvantage of this skin model currently used to mimic the 
stratum corneam is that it does not fully reflect the stratum corneam multicomponent structure 
therefore most of the times underestimate absorption of the drug [11-13].   However, Jurij et al. 
[13] have determined the skin permeability coefficient (Kp) for glycyl-L-histidyl-L-lysine cuprate 
diacetate in vitro and found it to be 2.43 ± 0.51x10
-4
 cm/h using an isolated stratum corneum 
(model membrane) and therefore predicted that copper as tripeptide complex will be delivered in 
potentially therapeutically effective amounts for inflammatory disease.   Encouraged by the 
copper (II) speciation results, which showed the formation of a ML species in significant amount 
(i.e. ≈ 70%) in solution at physiological pH range (i.e. between pHs 7.3-8.5) (see Figure 6.5 (a)) 
dermal absorption of Cu(II)-PCU.homo has been studied.   The rigid hydrophobic cage structure 
is believed will improve the dermal absorption of copper (II). Pehourcq et al. [14] have 














of PCU.homo and when compared to other complex in their study it was reported that the Kow for 
PCUA was higher due to the presence of the rigid cage. In vitro dermal absorption studies for the 
Cu(II)-PCU.homo were done using a modified Franz diffusion cell (i.e. a horizontal design).   A 
modified Franz cell was used in this study because setting up an industrial Franz cell is difficult 
and impractical because of its vertical design and it also requires large sample volumes.  
It is important to note that the porous lipid membrane used in drug diffusion studies must have 
the following physicochemical properties hydrophobicity, rate limiting properties like the stratum 
corneam and must have negligible resistance (i.e. small lag time) to the drug diffusion through, so 
as to not mask the effect the drug has on the diffusion of the metal ion [5, 8]. 
 
5.2.4 Franz diffusion cells apparatus 
The drug diffusion test were undertaken at room temperature on a validated tailor made Franz 
cell.   This apparatus is made of glass and consists of two compartments, a donor phase, where a 
model membrane lipidic system was placed and an acceptor phase where solutes accumulate after 
crossing the membrane barrier.   The acceptor phase was in close contact with the membrane 
during the experiment and was kept at physiological pH of 7.2.   The effective diffusion area was 
3.14 cm
2
 and the volume of the acceptor phase was 50 ml. 
 
5.2.5 Preparation of the 1:2 molar ratio Cu (II)-PCU.homopiperazine complex (diffusant). 
The solution of the approximately 1:2 (v/v) molar ratio copper complex was prepared from 
standards in deionized water, by adding 10 ml of 10 mM copper (II) solution to 20 ml of 7.6 mM 
PCU.homopiperazine solution (prepared and standardised using Gran plot see Chapter 2).   The 
pH of the solution was then raised to 7.2 by adding small amounts of NaOH solution and stored 
















5.2.6 Preparation of a membrane for use in Franz cell. 
In this study the Franz cell was used with a synthetic membrane, which was used to mimic the 
human skin.   The lipid membrane was prepared by soaking trimmed circular discs of Watman 
filter paper into a Cerasome 9005 (purchased from Lipoid GmbH Germany) membrane solution 
for 3hrs and taken out with tweezers to dry over air.   Each membrane was weighed before being 
used in the experiment. 
 
5.2.7 Franz diffusion cell studies and sample analysis. 
In this method, the cell consisted of two compartments of the same height and diameter, that is a 
donor phase cell (containing the 30 ml of copper (II)-ligand solution in water at pH 7.2) and the 
acceptor phase (containing deionized water at the same pH and volume as the donor phase) with a 
lipid membrane sandwiched between the two compartments.   The pH of the acceptor phase was 
maintained in the physiological range, because the lower layer of the statum cornium is 
maintained at physiological pH of 7-7.6. The acceptor phase liquid was kept homogenous 
throughout the diffusion experiment by using a magnetic stirrer.  The membrane sizes (i.e. mass 
and thickness) were be kept constant for every new diffusion experiment undertaken.   Both the 
air openings of the cell’s compartments were closed with parafilm to prevent sample evaporation 
and the development of air bubbles was stopped by tilting the apparatus a little.   Equal amounts 
(i.e. 7 ml) of samples from the donor and acceptor phase were taken using a glass syringe and 
poured into 10 ml glass vials at pre-set time intervals.   The volumes of the liquid in both cell 
compartments must be maintained equal to cancel out the effects of hydrostatic pressure on the 
diffusion of the copper (II) complex in solution throughout the experiment [14].   The extracted 
sample from the acceptor phase was then analysed using atomic absorption spectroscopy at 
324,7nm for copper (II) absorbance.   The cumulative amounts of the copper (II)-ligand in the 















5.3 Results and discussion 
5.3.1Franz cell 
The accumulative amounts of Cu(II)-homopiperazine and Cu(II)-PCU.homopiperazine per unit 
area across cerasome 9005 membrane over 24 hrs are plotted in Figure 5.2.   The flux values, 
permeability coefficient and their corresponding standard deviation (SD) of two complexes are 
shown in Table 5.1.   From Figure 5.2, it can be seen that the diffusion of the copper complexes is 
very slow for the first 8 hours of the experiment.   This is followed by a further phase of rapid 
diffusion called the steady state from 8 to 24 hours.   The reason for the observed induction 
period was attributed to the development of equilibrium between the donor phase and the 
membrane as a result of the complex diffusing through it [11, 17].  
 
Figure 5.2(a). Plots of Copper diffusion of Cu(II)-homopiperazine and Cu(II)-
PCU.Homopiperazine through cerasome 9005 membrane. (b) Plots of copper diffusion of 
CuPCU.homo, CuGly (copper(II)- Glycinate), CuH(555-N) (copper(II)- N-(2-(2-
aminoethyl)ethyl)picolinamide), and CuDTPA (copper(II)- diethylenetriamine-N,N,N’,N’’,N”-
pentaacetic acid. 
(a)                                                                         (b) 















Upon comparing the diffusion process of CuPCU.homo, CuGly (copper(II)- Glycinate), 
CuH(555-N) (copper(II)- N-(2-(2-aminoethyl)ethyl)picolinamide), and CuDTPA (copper(II)- 
diethylenetriamine-N,N,N’,N’’,N”-pentaacetic acid, each complex showed a similar trend (i.e. 
biphasic diffusion behaviour) as shown in Figure 5.2( b) which was also concluded as being 
caused by the development of a equilibrium between the donor phase and the membrane.   
 
5.4.2 Flux (J) and permeability coefficient (Kp) calculations 
The steady states flux and permeability coefficients of Cu(II)-PCU.homo were calculated from 
the gradient of the curves in Figure 5.2 (a).   The flux obtained for the Cu(II)-
PCU.homopiperazine complex and the values of other copper (II) complexes from literature are 




s, concentration (ppm) 








s and permeability 
coefficient Kp (mean ± SD) 10
-6 
cm/s through cerasome 9005 membrane 
 




s Kp (mean ± SD) 10
-6 
cm/s Ref 
CuPCU.homo 1.07± 0.04 5.06± 0.03  
CuHP 1.79± 0.01 5.63± 0.04  
CuDTPA 0.690± 0.004 2.17± 0.01 14 
CuPrDH 0.724 ± 0.003 2.28± 0.01 14 
CuGly 1.84±0.01 5.79±0.04 14 















Figure 5.3. The influence of various ligand systems on the flux of copper ions through a cerasome 
9005 membrane lipid membrane. 
 Figure 5.3 shows the influence of the different ligand systems on the flux of copper ions through 
the cerasome membrane.   These results suggest that the complexation of Cu(II) ions by the 
different ligands greatly influences the diffusion of copper ions across the membrane, because 
different flux values are obtained for different copper (II) complexes studied.   The following 
order of CuH(555-N) > CuGly > CuHP > CuPCU.homo > CuPrDH > CuDTPA was obtained. 
Comparing the permeation coefficient KP of copper complexes of PCU.homopiperazine and 
homopiperazine, there is a decrease in Kp in moving from homopiperazine to 
PCU.homopiperazine and this was attributed to the higher molecular weight of 
PCU.homopiperazine.   A similar effect of molecular weight (MW) of complex on the flux of 
copper complexes was also observed and reported by Potts et al, and this effect can be obtained 
quantitatively from their equation based on two physicochemical properties of octanol-water 
partition coefficient logKow and molecular weight MW of complex and is given by the linear 
relationship [11], 





























Where Dº represents the diffusivity of a hypothetical molecule having zero molecular weight, h is 
the membrane length in cm and β is a constant. 
Table 4.2: Physicochemical parameters and Permeability coefficient (Kp (mean ± SD) 10
-6 
cm/s) 
of 6 copper (II) complexes 
Complexes Molecular Weight 
(MW) g/mol 




% Cu complex 
concentration 
(ppm) 
Log  β -Log Kow 
[14]
 
CuPCU.homo  416.51 g/mol 5.06± 0.03 80 MLH 9.25  
CuHP  163.14 g/mol 5.63± 0.04 100 ML 7.60 3.49±0.01 
CuDTPA  414.77 g/mol 2.17± 0.01 70 ML 8.69 3.62±0.01 
CuPrDH  314.79 g/mol 2.28± 0.01  100 MLH-1 5.00 3.45±0.02 
CuGly 138.566 g/mol 5.79±0.04  100 ML2 8.15 2.661±0.003 
CuH(555-N) 288.768 g/mol 7.60±0.03  100 MLH-1 11.513 3.005±0.007 
 
Table 5.2 is the summary of Molecular Weight (MW), % Cu complex concentration (ppm), Log  
β, and  the permeation coefficient Kp (mean ± SD) 10
-6 
cm/s of the four copper (II) complexes.    
It has already been established by Jackson et al. that the diffusion (Kp) of the five copper (II) 
complexes (i.e. CuH(555-N), CuGly CuHP, CuPrDT and CuDTPA) across cerasome 9005 
membrane is linearly dependent on their octanol/water partion coefficient Kow, with Kp increasing 
with the increase in Kow [13].   Therefore in this study it was assumed that permeation coefficient 
(Kp) of CuPCU.homo too is affected by its Kow, since Pehourcq et al. [11] showed how the 
addition of a hydrophobic rigid cage on a Cu(II)-polyamine-diamine complex drastically 
improves the partion coefficient Kow of this polyamine-diamine complexes.   A value of Log Kp = 
-5.30 ± 0.03 obtained for CuPCU.homo in this study and was comparable to the value Log Kp = -
7.17 ± 0.51 reported by Hostynek et al. for the diffusion of a copper (II)-tripeptide complex in 
vitro using isolated stratum corneam [8], therefore giving confidence to the result obtained.   
From Table 4.2, since the permeability across the lipid membrane of the each complex is affected 














than for Cu-PCU.homo because the latter complex in solution at pH 7.2 it exists as a charged 
species (MLH) while CuGly exists as a neutral ML2 (100%) species at the same pH value.   
Similarly Kobayashi et al. 
[15] 
have also reported that the human nail permeability of several 
model drug derivatives of p-hydroxybenzoic acid esters where markedly decreased in the ionic 
homologues than in their non-ionic homologues.   For example the Kp of pyridine (Kp 6.36 x 10
7
 
cm/s of non-ionic) and Kp for Mexilentin hydrochloride ( Kp 0.202 x 10
7
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6. GENERAL DISCUSSION AND CONCLUSION 
The equilibrium constants of H
+
, Cu(II) and Zn(II) at 25˚C in 0.15 mol.dm-3 [NaCl] with ligands, 
homopiperazine and PCU.homopiperazine were investigated using glass electrode potentiometry. 
Potentiometric data analysis using ESTA showed that PCU.homopiperazine takes four protons in 
the pH range 2-11.   Furthermore PCU.homopiperazine presents two of its secondary amines as 
moderate to strong bases with the remaining amines behaving as weak bases.  This trend is 
consistent with many reported protonation sequence of polyamine systems.    The observed 
protonation constants agreed with those from related tetra-amine ligands and their analogues.   
The reasonably low standard deviation in the log βpqr’s and the low Hamilton R-factor give 
confidence to the chosen model to explain the protonation system of PCU.homopiperazine.   
Furthermore, from NMR spectroscopy studies, the graphs of chemical shifts as function of 
solution pH were successfully used to obtain the micro-protonation constant of the terminal 
amines pKa = 10.1 and 9.0.   These are comparable to the first two protonation constants on 
PCU.homopiperazine determined from potentiometry. 
PCU.homopiperazine formed more stable complexes with copper (II) than with zinc (II).  The 
tetragonally distorted ML species was the dominant species under physiological conditions.   The 
tetragonally distorted arrangement of PCU.homopiperazine with three donor atoms around the 






 respectively, has been 
suggested on the basis of UV/Vis spectrophotometric measurement (see Figure 4.1(b)) and 
Billo’s test.  This preferred coordination geometry in ML species was further supported by NMR 
spectroscopy and MM calculations.   The weak stability in the Zn(II)-PCU.homopiperazine 
system was attributed to being caused by the cyclic nature of the ligand ‘homopiperazine’ which 
is believed to find it difficult to form a tetrahedral geometry around zinc(II) ion, and this leads to 














The primary objective of this study was to produce a drug which is able to mobilize Cu(II) in 
blood plasma.   Zn(II) and Ca(II) ions, being present in the blood plasma in large concentrations 
are regarded as potential competitors of Cu(II) in vivo.   Since no complexation was detected for 
the Zn(II)-PCU.homopiperazine system, it was not included since these metal ions would not 
compete effectively in vivo.   The plasma mobilising index of PCU.homopiperazine was 
determined and compared to p.m.i of Homopiperazine.   The order of metal ion selectivity and 
mobilizing ability of these two ligands is given by PCU.homopiperazine > homopiperazine.   
However the model showed that PCU.homopiperazine is not good in mobilizing copper in vivo, 
with 0.01M needed to cause a 10 fold increase in the l.m.w concentration of Cu(II).   It was also 
established that PCU.homopiperazine is between 4 and 6 orders of magnitude poorer in 
mobilizing copper (II) when compared to the previously studied related pentacyclo-undacane 
(PCUA) derivatives.  Therefore PCU.homopiperazine-Cu(II) complexes is predicted to dissociate 
in blood plasma. However all was not lost as the ligand could still be used to improve the dermal 
absorption of copper (II). 
A simple empirical model of the skin was constructed for predicting the in vivo permeability 
coefficient in water at pH 7.2, for the transdermal delivery of CuGly, CuH(555-N), 
CuPCU.homo, CuHP, CuPrDT and CuDTPA respectively. CuH(555-N) was found to increase 
the dermal absorption of copper (II) the most when compared to the rest of the ligand systems in 
this study with Kp = 7.60 x 10
-6 
cm/s. The permeability across the lipid membrane of the 
CuPCU.HP complex was concluded to be affected by its hydrophobicity.   The permeation 
coefficient Kp of CuGly (Kp = 5.79 x 10
-6 
cm/s) is higher than that of Cu-PCU.homo (Kp = 5.06 x 
10
-6 
cm/s) because the latter complex in solution at pH 7.2 exists as a charged species MLH while 
Cu-Gly exists as an ML2 (100%) species at the same pH value. A value of Log Kp = -5.30 ± 0.03 














reported by Hostynek et al. for the diffusion of a copper (II)-tripeptide complex in vitro using 
isolated stratum corneam, therefore giving confidence to the results obtained in this study. 
Judging from the result obtained in this study, more work has to be done in developing new 
knowledge and understanding of factors that affect the coordination of copper (II) chelating 
agents, so as to improve the efficacy of the copper complexes used in the alleviating 
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Figure 1.1:  Picture of a hand affected with RA  
Figure 1.2: Structure of PCU.homopiperazine (pentacycloudecane,-bis1, 2-1,4diazacycloheptane) 
and Homopiperazine (1,4diazacycloheptane) 
Figure 2.1(a): Protonation formation curve, ZH-bar plotted against pH for homopiperazine at 25º 
C in 0.15 M NaCl. The symbols represent titrations performed at different initial concentrations, 
and the solid theoretical line. 
Figure 2.1(b): Protonation species percentage distribution curves of homopiperazine 
([L]T=1.0mM) as a function of pH. 
Figure 2.2(a): formation function curve, ZM-bar against pL for Homopiperazine at 25ºc in 0.15 M 
NaCl. The symbols represent complexation curves for various metals to ligand ratios, [(▄) 1:1, 
(▲) 1:2 and (●) 1:3) and the theoretical curve is the solid line 
  
Figure 2.2(b): Complex species percentage distribution curves of Homopiperazine-copper system 
(1:2 ratios) as a function of pH. 
 
Figure 2.3(a): protonation formation curve, ZH-bar plotted against pH for PCU.Homopiperazine 
at 25º C in 0.15 M NaCl. The symbols represent titrations performed at different initial 
concentrations, and the solid theoretical line. 
 
Figure 2.3(b): Protonation species percentage distribution curves of PCU.Homopiperazine 
([L]T=7.5230mM) as a function of pH. 
 
Figure 2.4: Protonation scheme for PCU.Homopiperazine. 
 
Figure 2.5(a): Formation function curve, ZM-bar against pL for PCU.Homopiperazine-Copper (II) 
at 25ºc in 0.15 M Na+ Cl-. The symbols represent complexation curves for various metals to 
ligand ratios, [(▄) 1:3, and (▲) 1:2 and the theoretical curve is the solid line. 
 
Figure 2.6 (b): Complex species percentage distribution curves of Homopiperazine-copper system 
(1:2 ratios) as a function of pH. 
 

















H NMR spectra of PCU.Homopiperazine as a function of pH. Chemical shifts are 






H correlated spectrum (COSY) of a solution of PCU.Homopiperazine at 25º C 






C Heteronuclear Correlation spectrum (HSQC) of 7.9952 mM 
PCU.Homopiperazine solution at 25ºC in D2O at Ph = 8. Chemical shifts are given relative to 
tertiary butyl alcohol as an internal standard.  
 








H NMR spectra for complexation of copper (II) with PCU.Homopiperazine as a 
function of copper (II) concentration. 
 
Figure 3.4: change in proton chemical shift (ppm) as a function of pH for PCU.Homopiperazine. 
 
Figure 4.1(a): Electronic spectra of solution of Cu (II) and PCU.HP as a function of wavelength. 
Figure 4.1(b) Deconvoluted electronic spectra of solution of Cu (II) - PCU.HP system as a 
function of wavelength 
 
Figure 4.2: Proposed structures for the different copper (II) complexes species with 
PCU.Homopiperazine with their respective wavelength max, predicted using Billo’s method. 
Figure 4.3: force fields, which are used in this calculation, contain the energy terms listed below 
[Brooks et al., 1983]: 
 
Figure 4.4: shows possible isomers for the different species formed by the Cu (II)-
PCU.Homopiperazine calculated using Insight (II). Table 4 lists the different contributions to the 
strain energy calculated using Insight (II). 
 
Figure 5.1(a): P.m.i curve for PCU.Homopiperazine and Homopiperazine in blood plasma at pH 
7.43. 
Figure 5.1(b): P.m.i curve calculated for different ligands in blood plasma. 
 
 
Figure 5.2(a). Plots of Copper diffusion of Cu(II)-homopiperazine and Cu(II)-
PCU.Homopiperazine through cerasome 9005 membrane.  
 
Figure 5.2(b): Plots of copper diffusion of CuPCU.homo, CuGly (copper(II)- Glycinate), 
















Figure 5.3: The influence of various ligand systems on the flux of copper ions through a cerasome 
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